🔗

Mappings

MONDO

MONDO:0011193 cone dystrophy 3 Not Yet Curated

Cone dystrophy 3 (COD3) is the historical cone-restricted presentation of GUCA1A-related retinopathy and a child term of MONDO:0700376.

MONDO:0800326 cone-rod dystrophy 14 Not Yet Curated

Cone-rod dystrophy 14 (CORD14) is the child term for GUCA1A-related presentations with secondary rod involvement.

👪

Inheritance

1

Autosomal dominant HP:0000006

Heterozygous gain-of-function missense variants in GUCA1A cause autosomal dominant GUCA1A-related retinopathy. Each child of an affected parent has a 50% chance of inheriting the pathogenic variant.

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:9425234 SUPPORT Human Clinical

"We report a mutation (Y99C) in guanylate cyclase activator 1A (GUCA1A), the gene for guanylate cyclase activating protein (GCAP1), in a family with autosomal dominant cone dystrophy."

Payne et al. establish the founding GUCA1A Y99C mutation as the cause of autosomal dominant cone dystrophy in the original discovery pedigree.

⚙

Pathophysiology

7

GCAP1 Loss of Calcium-Dependent Inhibitory Control

Dominant missense variants in GUCA1A cluster in the EF-hand calcium-binding loops of GCAP1 (e.g. EF3 for the founding p.Tyr99Cys variant, EF4 for p.Asp144Gly), impairing the protein's ability to sense rising dark-adapted Ca2+ and switch into its RetGC-inhibiting conformation. The founding p.Tyr99Cys variant does not decrease GCAP1's ability to activate RetGC, but the resulting RetGC-GCAP1 complex remains active even at Ca2+ concentrations above 1 microM, well into the physiological dark-adapted range, rather than being suppressed as normal GCAP1 would suppress it. Other variants (p.Asn104His, p.Leu176Phe, p.Asp144Gly) act through related biophysical mechanisms: impaired Ca2+ sensitivity, altered Mg2+/Ca2+ exchange kinetics, or increased binding affinity for RetGC, all converging on loss of the normal Ca2+-dependent brake on cyclase activation.

retinal cone cell CL:0000573 retinal rod cell CL:0000604

GUCA1A hgnc:4678 ⇑ GAIN OF FUNCTION

Genetic context GUCA1A hgnc:4678 allele_type: MISSENSE variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: GAIN_OF_FUNCTION

Monoallelic missense variants that leave GCAP1's capacity to activate RetGC intact and remove its Ca2+-dependent off-switch, so the variant acts by adding constitutive activation rather than by abolishing function.

detection of calcium ion GO:0005513 ↓ DECREASED

Downstream

RetGC Constitutive Hyperactivity A GCAP1 that can no longer be switched off by rising dark-adapted Ca2+ continues to drive RetGC catalytic activity regardless of the photoreceptor's light-adaptation state.

Show evidence (3 references)

PMID:9651312 SUPPORT In Vitro

"The Y99C mutation does not decrease the ability of GCAP-1 to activate RetGC. However, RetGC stimulated by the Y99C GCAP-1 remains active even at Ca2+ concentration above 1 microM. Hence, the cyclase becomes constitutively active within the whole physiologically relevant range of free Ca2+ concentrations."

Dizhoor et al. biochemically demonstrate that the Y99C GCAP1 mutant fails to lose its RetGC-activating conformation at high (dark-adapted) Ca2+, the direct molecular basis of loss of calcium-dependent inhibitory control.

PMID:28025326 SUPPORT In Vitro

"The mutant was less sensitive to changes in free Ca2+, resulting in a constitutively active form under physiological Ca2+-concentration, showed significantly higher activation rates than the wildtype (90-fold versus 20-fold) and interacted with an higher apparent affinity with its target..."

Vocke et al. show the L176F GCAP1 variant is biochemically less Ca2+-sensitive and binds RetGC with higher affinity, reproducing the same loss-of-calcium-control mechanism in a second, independently identified variant.

PMID:30679166 SUPPORT Other

"These result in persistent stimulation of RetGC, excess cGMP levels in the dark and photoreceptor apoptosis secondary to Ca2+ dysregulation."

Gill et al. summarize the shared consequence of the GUCA1A gain-of-function alleles, tying the EF-hand lesion to persistent RetGC stimulation. Classified OTHER because this is a narrative review synthesizing published cohorts rather than reporting primary observations.

RetGC Constitutive Hyperactivity

Constitutively activating mutant GCAP1 continues to stimulate retinal guanylate cyclase (RetGC1 and, for some variants, also RetGC2) even at Ca2+ concentrations characteristic of the dark-adapted state, when wild-type GCAP1 would normally suppress the enzyme. This produces chronically elevated cGMP synthesis that is no longer coupled to the light-dependent Ca2+ signal, independent of the ambient light state.

retinal cone cell CL:0000573

GUCA1A hgnc:4678 ⇑ GAIN OF FUNCTION

cGMP biosynthetic process GO:0006182 ↑ INCREASED

Downstream

Sustained CNG Channel Opening and Outer-Segment Calcium Overload Chronically elevated cGMP keeps cyclic nucleotide-gated (CNG) channels open independent of the light state, producing sustained Ca2+/Na+ influx into the photoreceptor outer segment.

Impaired Cone Light-Response Generation and Delayed Recovery A cyclase that is no longer gated by the light-driven fall in Ca2+ cannot shape the cone photoresponse, degrading the amplitude and the timing of the cone-driven light response.

Abnormal Photoreceptor-to-ON-Bipolar Synaptic Transmission In a minority of patients the dysregulated GCAP1-cyclase complex propagates past the outer segment to the photoreceptor synaptic terminal.

Show evidence (2 references)

PMID:34639157 SUPPORT In Vitro

"The altered interaction with GC would cause hyper-activity of the enzyme at both low and high Ca2+ levels, which would ultimately lead to toxic accumulation of cGMP and Ca2+ in the photoreceptor outer segment, thus triggering cell death."

Biasi et al. directly link the N104H GCAP1 variant's hyperactivation of guanylate cyclase to downstream toxic cGMP/Ca2+ accumulation, connecting the enzymatic hyperactivity node to the downstream calcium overload node.

PMID:15240799 SUPPORT Model Organism

"Y99C GCAP1 shifted the Ca2+ sensitivity of the guanylyl cyclase in photoreceptors, keeping it partially active at 250 nM free Ca2+, the normal resting Ca2+ concentration in darkness."

Olshevskaya et al. show in vivo that the Y99C transgene leaves the cyclase active at the resting dark Ca2+ concentration, confirming in a whole retina the set-point failure demonstrated biochemically.

Sustained CNG Channel Opening and Outer-Segment Calcium Overload

Chronically elevated cGMP holds cyclic nucleotide-gated channels open independent of the light state, so Ca2+ and Na+ enter the outer segment continuously and free Ca2+ rises above its normal dark level. This is the branch point at which a phototransduction set-point lesion becomes a degenerative rather than a stationary disease.

retinal cone cell CL:0000573

calcium ion transmembrane import into cytosol GO:0097553 ↑ INCREASED

Animal models

Y99C GCAP1 transgenic mouse Mouse recapitulates Direct in vivo measurement of elevated outer-segment free Ca2+ in darkness, with increased CNG channel activity, in an animal carrying the human founding variant.

Downstream

Cone Photoreceptor Degeneration Sustained calcium and cGMP elevation in the outer segment triggers photoreceptor cell death.

Variable Rod Photoreceptor Involvement GCAP1 is expressed in rods as well as cones, so the same set-point lesion can reach the rod population, later and in a minority of patients.

Show evidence (2 references)

PMID:15240799 SUPPORT Model Organism

"The enhanced activity of the cyclase in the dark increased cyclic nucleotide-gated channel activity and elevated the rod outer segment Ca2+ concentration in darkness"

Olshevskaya et al. measured the outer-segment Ca2+ rise directly in the Y99C transgenic retina, establishing that the channel opening and the calcium overload are real consequences of the cyclase lesion and not only an inference from biochemistry.

PMID:34639157 SUPPORT In Vitro

"The altered interaction with GC would cause hyper-activity of the enzyme at both low and high Ca2+ levels, which would ultimately lead to toxic accumulation of cGMP and Ca2+ in the photoreceptor outer segment, thus triggering cell death."

Biasi et al. name toxic cGMP and Ca2+ accumulation in the outer segment as the step between cyclase hyperactivity and photoreceptor death.

Impaired Cone Light-Response Generation and Delayed Recovery

Loss of the Ca2+-gated cyclase brake degrades the cone light response itself, separately from the degenerative arm. Cone-driven full-field ERG amplitudes are reduced in most affected patients, and in the most severely affected the 30-Hz flicker response is also delayed, which is the timing signature of a recovery defect rather than a pure amplitude loss.

retinal cone cell CL:0000573

regulation of opsin-mediated signaling pathway GO:0022400 ↓ DECREASED

Animal models

Y99C GCAP1 transgenic mouse Mouse fails to recapitulate Despite a measurable rise in dark outer-segment Ca2+, the rod photoresponse in these mice was largely unchanged, so the model does not reproduce the light-response failure seen on human cone-driven ERG.

Downstream

Abnormal electroretinogram Reduced and delayed cone-driven responses are what the clinical full-field and pattern ERG records.

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"Ten of 13 subjects had subnormal LA 30-Hz or LA 3 (single-flash) ERGs"

Allon et al. quantify reduced cone-driven light-adapted ERG responses in the majority of tested patients, the functional readout of failed cone light-response generation.

PMID:39969478 SUPPORT Human Clinical

"there was an additional LA 30-Hz ERG delay in the 5 with the smallest LA responses"

The flicker peak-time delay in the most severely affected patients is the timing abnormality that distinguishes a recovery defect from a simple loss of responding cones.

Abnormal Photoreceptor-to-ON-Bipolar Synaptic Transmission

In some patients the dysregulated GCAP1-cyclase complex disturbs signaling at the photoreceptor synaptic terminal rather than only in the outer segment, producing an attenuated b-wave and an electronegative ERG waveform that indicate an ON-pathway transmission defect.

retinal cone cell CL:0000573 retinal bipolar neuron CL:0000748

synaptic transmission, glutamatergic GO:0035249 ↓ DECREASED

Downstream

Abnormal electroretinogram The ON-pathway transmission defect appears clinically as a negative ERG waveform with an attenuated b-wave.

Show evidence (2 references)

PMID:33919796 SUPPORT Human Clinical

"the abnormal electroretinogram recorded in this patient also suggested that the dysregulation of the GCAP1-cyclase complex further propagates to the synaptic terminal, thereby altering the ON-pathway related to the b-wave generation"

Marino et al. report ERG evidence in a patient carrying a double GCAP1 substitution (N104K/G105R) that dysregulated GCAP1-RetGC signaling also disturbs synaptic transmission to ON-bipolar cells.

PMID:33919796 SUPPORT Human Clinical

"Severe alterations of the electroretinogram were observed under both scotopic and photopic conditions, with a negative pattern and abnormally attenuated b-wave component."

The negative ERG waveform with attenuated b-wave is the specific electrophysiological signature of inner-retinal transmission failure rather than outer-segment loss alone.

Cone Photoreceptor Degeneration

Persistent calcium and cGMP elevation triggers photoreceptor cell death. Cones bear the earliest and most severe toxicity because GCAP1 expression is higher in cones and cone recovery kinetics depend on it more heavily, with later, more variable rod and macular RPE involvement depending on the specific variant.

retinal cone cell CL:0000573

apoptotic process GO:0006915 ↑ INCREASED photoreceptor cell maintenance GO:0045494 ↓ DECREASED

Animal models

Y99C GCAP1 transgenic mouse Mouse partially recapitulates Photoreceptors degenerate in these mice at a rate scaling with transgene expression, and do not degenerate in mice overexpressing wild-type GCAP1, isolating the variant as the cause.

GCAP1 RNAi knockdown rescue models Mouse rescues Knocking down mutant GCAP1 enhanced photoreceptor survival, delayed degeneration onset, and improved visual function in both lines, which is the interventional counterpart of the claim that GCAP1 gain of function drives the degeneration.

GUCA1A p.Arg120Leu zebrafish overexpression model Zebrafish partially recapitulates Mutant-injected larvae lost cone inner-segment and outer-segment staining and cone cell-body signal, and co-injected wild-type mRNA did not rescue the loss, which is the behavior expected of a toxic gain-of-function allele rather than a haploinsufficiency.

Downstream

Progressive visual loss Loss of central cones is what patients experience as progressive decline in central visual acuity.

Color vision defect Cone loss removes the substrate for color discrimination, which is why dyschromatopsia is the commonest presenting symptom.

Macular atrophy Degeneration of the central cone population appears structurally as ellipsoid-zone disruption and then macular atrophy on OCT.

Photophobia A degenerating and dysfunctional cone population underlies the light sensitivity reported by most affected patients.

Central scotoma Loss of the central cone population produces the central and paracentral field defects found on perimetry.

Reduced visual acuity Loss of the central cone population is what the measured logMAR acuity records at any one visit.

Show evidence (2 references)

PMID:15240799 SUPPORT Model Organism

"However, the photoreceptors in these mice degenerated, and the rate of the cell loss increased with the level of the transgene expression, unlike in transgenic mice that overexpressed normal GCAP1."

Dose-dependent photoreceptor loss with the mutant but not the wild-type transgene establishes that degeneration follows from the variant rather than from GCAP1 overexpression as such.

PMID:30679166 SUPPORT Other

"The relative preservation of rod responses in most GUCA1A-associated progressive retinal dystrophies is attributed to greater GCAP1 expression in cones."

Gill et al. give the reason cones are affected first, which is the claim this node makes about the cell-type selectivity of the degeneration. Classified OTHER because this is a narrative review.

Variable Rod Photoreceptor Involvement

GCAP1 is expressed in rods as well as cones, so the rod population is not immune to the same cGMP and calcium set-point lesion. Rod involvement is the exception rather than the rule: dark-adapted rod-specific ERGs were normal in almost every tested patient, and peripheral pigmentary change appeared in 2 of 19. Where it occurs it marks the cone-rod end of the phenotypic range, not a conversion to a rod-first disease.

retinal rod cell CL:0000604

photoreceptor cell maintenance GO:0045494 ↓ DECREASED

Downstream

Peripheral pigmentary retinopathy Rod and outer-retinal involvement at the periphery appears on ultra-widefield imaging as pigment spicules.

Nyctalopia Rod dysfunction, where it occurs, is what a patient reports as night blindness.

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"In the latter patient, the nature and progression of symptoms were still more in keeping with a cone-rod, rather than a rod-cone, dystrophy, and other family members did not show the pigmentary changes."

Even in the patient with peripheral pigmentary change, the course stayed cone-rod. This is the evidence for scoping this node as variable involvement rather than as a rod-degeneration arm.

PMID:30679166 SUPPORT Other

"The relative preservation of rod responses in most GUCA1A-associated progressive retinal dystrophies is attributed to greater GCAP1 expression in cones."

Gives the reason rods are relatively spared, which is the same claim this node makes from the other side: rods carry the lesion but at lower GCAP1 dose. Classified OTHER because this is a narrative review.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

9

Progressive visual loss VERY_FREQUENT Ophthalmological HP:0000529

Course: PROGRESSIVE Onset: YOUNG ADULT; mean 23.0y (range 5.0-74.0y)

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"Most had progressive visual loss and electrophysiologic evidence of cone dystrophy."

Allon et al. report progressive visual loss as the predominant clinical course in the largest reported GUCA1A cohort (19 patients, 14 families).

PMID:39969478 SUPPORT Human Clinical

"The mean (SD) age of onset of symptoms was 23 (17) years (range, 5–74 years)."

Source for the onset descriptor: mean age of symptom onset and its full reported range in the same cohort.

Reduced visual acuity VERY_FREQUENT Ophthalmological HP:0007663

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"Acuities ranged from 0.00 logMAR to no light perception."

Allon et al. document the full range of visual acuity severity observed across the GUCA1A cohort, from near-normal to no light perception.

Context-specific annotations (1)

MALE

In a mixed-effects model across 144 visits, male sex was associated with worse visual acuity independent of age. The cohort was 68.4% male and the authors treat the association as provisional.

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"male sex was associated with worse acuity (P = 0.023)"

Reports sex as a modifier of acuity severity within the GUCA1A cohort.

Color vision defect VERY_FREQUENT Ophthalmological HP:0000551

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"Overall, across the entire duration of follow-up, 17 patients (89.5%) reported central vision deficits, 16 patients (84.2%) described color vision deficits, 15 (78.9%) reported some degree of photophobia"

84.2% of the cohort described color vision deficits, which places the frequency in the VERY_FREQUENT band (80-99%).

PMID:39969478 SUPPORT Human Clinical

"Thirteen patients (68.4%) described poor color discrimination as their initial symptom"

Color vision impairment is also the commonest presenting symptom, which is why it is treated as the early feature of the disease.

Photophobia FREQUENT Ophthalmological HP:0000613

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"Overall, across the entire duration of follow-up, 17 patients (89.5%) reported central vision deficits, 16 patients (84.2%) described color vision deficits, 15 (78.9%) reported some degree of photophobia"

78.9% of the GUCA1A cohort reported photophobia, which sets the FREQUENT band (30-79%) just below the VERY_FREQUENT threshold.

PMID:30679166 SUPPORT Other

"These disorders typically present with progressive loss of central vision, colour vision disturbance and photophobia."

Supporting class-level characterization of photophobia as a typical presenting feature of progressive cone and cone-rod dystrophies, of which GUCA1A is one of the four commonest causes. Classified OTHER because this is a narrative review, and it is a second item behind the GUCA1A-specific figure rather than the source of the frequency band.

Abnormal electroretinogram VERY_FREQUENT Electrophysiological HP:0000512

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"Electrophysiology (n = 13) was consistent with cone dystrophy (n = 11) or macular dystrophy (n = 2)."

Allon et al. report electrophysiological findings consistent with cone dystrophy in the large majority of tested patients in the GUCA1A cohort.

PMID:30679166 SUPPORT Other

"ERG studies characteristically show reduced cone single-flash and flicker amplitudes with a normal implicit time"

Describes the characteristic GUCA1A ERG signature. Classified OTHER because this is a narrative review. Note that the Allon cohort did find a flicker peak-time delay in its five most severely affected patients, so the normal implicit time described here holds for milder disease and is not universal.

Macular atrophy VERY_FREQUENT Ophthalmological HP:0007401

Course: PROGRESSIVE

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"Maculopathy was evident in all individuals on OCT imaging."

Structural macular involvement was universal (19/19) on OCT, which sets the VERY_FREQUENT band. The macular-dystrophy ERG pattern seen in 2 of 13 tested patients is a separate, rarer electrophysiological finding and is recorded on the electroretinogram phenotype, not here.

PMID:39969478 SUPPORT Human Clinical

"Optical coherence tomography showed irregularity and then loss of the central ellipsoid zone."

Documents the progressive structural sequence on OCT underlying the atrophy.

Central scotoma OCCASIONAL Ophthalmological HP:0000603

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"Visual field tests, where performed (four patients), demonstrated central and paracentral scotomas."

Central and paracentral scotomas were found in all four patients who underwent perimetry. The frequency band is set on the 4 of 19 who were tested rather than on the 4 of 4 who were positive, because the cohort denominator is what the band describes and the untested patients are unknown rather than negative.

Peripheral pigmentary retinopathy OCCASIONAL Ophthalmological HP:0007737

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"Peripheral involvement with pigment spicules was noted in two individuals"

2 of 19 patients (10.5%) had peripheral pigmentary change, which places the frequency in the OCCASIONAL band (5-29%).

Nyctalopia OCCASIONAL Ophthalmological HP:0000662

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"1 patient (IX-l) noted nyctalopia (5.3%)"

One of 19 patients (5.3%) reported nyctalopia, which falls in the OCCASIONAL band (5-29%) at its lower edge. The band rests on a single patient in a 19-patient series and should be revisited against a larger cohort.

🧬

Genetic Associations

1

GUCA1A pathogenic variants (Causative)

Gene: GUCA1A hgnc:4678

Autosomal dominant

Show evidence (4 references)

PMID:39969478 SUPPORT Human Clinical

"Nineteen patients (14 families), with five different variants, were included: p.(Tyr99Cys) in 10 families and p.(Leu84Phe), p.(Ile107Thr), p.(Glu111Ala), and p.(leu176Phe) in 1 family each."

Allon et al. document the variant spectrum and relative frequency of p.Tyr99Cys versus other GUCA1A variants in the largest reported cohort.

PMID:39969478 SUPPORT Human Clinical

"Compared with the common p.(Tyr99Cys) variant, patients with p.(Glu111Ala) (n = 2) had worse vision; those with p.(Leu84Phe) (n = 3) were younger with earlier-onset visual loss. Patients with p.(Ile107Thr) (n = 2) showed later presentation, with milder acuity reduction."

Allon et al. report preliminary genotype-phenotype correlations among the reported GUCA1A variants.

PMID:15953638 SUPPORT Human Clinical

"This is the first report of this mutation also causing both cone-rod dystrophy and isolated macular dysfunction."

Michaelides et al. found the single p.Tyr99Cys allele producing cone dystrophy, cone-rod dystrophy, and isolated macular dysfunction within one family. This is the direct evidence for modeling the disease as one umbrella entity rather than partitioning it into COD and CORD subtypes.

+ 1 more reference

💊

Medical Actions

2

Supportive care and low vision rehabilitation

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Platform: Other

No approved disease-modifying treatment exists for GUCA1A-related retinopathy. Standard of care encompasses low vision aids, tinted lenses or filters for photophobia, orientation and mobility support as needed, and regular monitoring of visual function and retinal structure to track progression.

Genetic counseling

Action: Genetic Counseling NCIT:C15240

Platform: Other

Genetic counseling clarifies the 50% recurrence risk to offspring of an affected individual under autosomal dominant inheritance, supports cascade testing of at-risk relatives, and informs family planning and eligibility for future clinical trials as they become available.

🔬

Diagnosis

3

Molecular genetic testing

Targeted Sanger sequencing, gene-panel sequencing, or exome/genome sequencing establishes the diagnosis. Variants are classified by ACMG criteria and annotated against the MANE select GUCA1A transcript NM_001384910.1. Molecular confirmation matters because the clinical picture overlaps other dominant cone and cone-rod dystrophies, and because a peripheral pigmentary phenotype should prompt consideration of alternative genetic causes.

Genetic Testing NCIT:C15709

Results: Confirms a heterozygous pathogenic or likely pathogenic GUCA1A missense variant, most often p.Tyr99Cys, and enables cascade testing of relatives.

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"Variant classification ascribing likely pathogenicity was performed in accordance with American College of Medical Genetics and Genomics (ACMG) guidelines."

Documents the variant-classification standard applied in the reference cohort.

PMID:39969478 SUPPORT Human Clinical

"Variants were annotated in relation to the most biologically relevant MANE select GUCA1A transcript NM_001384910.1."

Names the reference transcript against which GUCA1A variants should be reported.

Multimodal retinal imaging

Spectral-domain OCT, fundus autofluorescence, and ultra-widefield pseudocolor fundus photography together stage the maculopathy. Fundus autofluorescence is the most sensitive of the three for early macular involvement, and ultra-widefield imaging is what detects the uncommon peripheral pigmentary change.

Optical Coherence Tomography NCIT:C20828

Results: OCT shows ellipsoid-zone irregularity progressing to partial then complete loss, with an optical gap between the neurosensory retina and the RPE at early stages; autofluorescence shows macular involvement that may precede any visible fundus change.

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"Fundus autofluorescence demonstrated high sensitivity in detecting maculopathy and in some cases was able to identify macular involvement before findings were apparent on clinical examination or color or pseudocolor fundus images, although the OCT was usually abnormal."

Establishes the relative sensitivity of autofluorescence and OCT for early macular involvement in this disease.

Visual electrophysiology

ISCEV-standard full-field and pattern electroretinography separate generalized cone-system dysfunction from macular-only disease and quantify severity. Pattern ERG P50 measures macular function; full-field light-adapted responses measure generalized cone function; dark-adapted responses test the rod system, which is usually spared.

Retinal Examination NCIT:C101217

Results: Most patients show a cone dystrophy pattern with reduced light-adapted responses; a minority show a macular dystrophy pattern with normal full-field ERGs. A negative waveform with attenuated b-wave points to the ON-pathway transmission variant of the disease.

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"ERG findings were consistent with cone dystrophy in 11 subjects and with macular dystrophy in 2 cases"

Shows how the ERG separates the generalized cone-dystrophy pattern from the macular-restricted pattern in this cohort.

📈

Progression

3

Symptomatic onset

Age: Second to third decade, with a reported range from age 5 to 74

Onset is typically in the second or third decade, most often as impaired color discrimination or loss of central vision. The mean age at symptom onset across the largest cohort was 23 years, but the range was wide and a minority present in childhood or after the sixth decade.

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"The mean (SD) age of onset of symptoms was 23 (17) years (range, 5–74 years)."

Gives the mean and range of symptom onset in the 19-patient cohort.

PMID:30679166 SUPPORT Other

"Symptomatic onset usually occurs between the second and third decade with reduced central vision, photophobia and generalised dyschromatopsia."

Independent characterization of the typical decade of onset and its presenting symptoms. Classified OTHER because this is a narrative review.

Gradual acuity decline

Age: Across adult follow-up

Visual acuity worsens with age at roughly 0.20 logMAR per decade, fitted across 144 patient visits in a mixed-effects model. The decline is gradual and highly symmetric between eyes, and vision may remain relatively preserved beyond the seventh decade in some patients.

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"it corresponded roughly to a worsening of approximately 0.20 logMAR per decade"

Quantifies the rate of visual acuity decline in the largest cohort.

Structural macular progression

Age: Tracks acuity rather than age alone

OCT changes begin as mild ellipsoid-zone irregularity, advance to partial disruption of the layer as acuity falls toward 0.3 logMAR, and reach more complete loss of the photoreceptor layer years later once acuity falls below 0.7 logMAR, with outer nuclear layer and RPE involvement following. The staging tracks visual acuity more closely than chronological age: the cohort mean age was similar at the partial-disruption and complete-loss stages, and the reported age ranges for the two overlap.

Show evidence (2 references)

PMID:39969478 SUPPORT Human Clinical

"In addition to the mild EZ irregularity typically observed in the early stages of the disease, partial EZ disruption was also observed as the disease progressed and visual acuity levels reached approximately 0.3 logMAR. More complete loss of the photoreceptor layer was subsequently noted years..."

Ties the two structural stages to the acuity levels at which they appear, which is how the cohort stages structural progression.

PMID:39969478 SUPPORT Human Clinical

"The changes observed on OCT scans begin with mild EZ irregularity, progressing to atrophy affecting outer retinal layers, including the outer nuclear layer, and RPE irregularity."

States the sequence of retinal layers involved as the maculopathy advances.

📊

Prevalence

2

United States

Point Prevalence 0.4 per 100,000 1–9 per 1,000,000

Derived from a US series of 1000 consecutive inherited retinal disease cases carrying 7 GUCA1A cases, from which the authors extrapolated a US-wide prevalence of 1 in 247,143. That is 0.4 per 100,000, or about 4 per million, which is the BAND_1_9_PER_1000000 class. The estimate is an extrapolation from a single referral cohort, not a population survey.

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"A US-based study of 1000 consecutive IRD cases found 7 cases with GUCA1A variants; the authors estimated a US-wide prevalence of 1 in 247,143 people."

States both the observed case count and the extrapolated population prevalence figure this record converts.

Inherited retinal disease clinic cohorts (US, UK, Spain, Germany, Japan, China)

Unknown Unknown

Across six published IRD cohorts, GUCA1A accounted for roughly 0.1% to 0.7% of patients or families. The denominator here is an inherited retinal disease clinic population, not a general population, so no magnitude band applies and the record is deliberately left unbanded. The authors note the spread also reflects differing genetic testing strategies and whether the denominator counts all IRD patients or only those with a positive molecular diagnosis.

Show evidence (1 reference)

PMID:39969478 SUPPORT Human Clinical

"Thus, the prevalence in IRD cohorts appears to range from roughly 0.1% to 0.7%."

Gives the cross-cohort range of the GUCA1A share of inherited retinal disease diagnoses.

🐁

Animal Models

3

Y99C GCAP1 transgenic mouse

Transgenic mice expressing the human disease allele Y99C GCAP1, generated in several lines with differing transgene expression levels. The model reproduces the molecular lesion, the dark-state calcium elevation, and dose-dependent photoreceptor degeneration.

Species

Mouse

Genotype

Transgenic expression of GCAP1 carrying the Tyr99Cys substitution

Publication

PMID:15240799

Pathograph links

Sustained CNG Channel Opening and Outer-Segment Calcium Overload recapitulates fidelity: high Direct in vivo measurement of elevated outer-segment free Ca2+ in darkness, with increased CNG channel activity, in an animal carrying the human founding variant.

Limitations: Measurements were made in rod outer segments, whereas human disease is cone-predominant, and the transgene is overexpressed rather than expressed from the endogenous locus. Severity tracks transgene dose, so the rate of degeneration in any one line is not a model of the human rate.

Readouts

Rod outer segment free calcium concentration in darkness

Free Ca2+ in dark-adapted rod outer segments, measured with fluo-5F and laser spot microscopy.

Direction: INCREASED

Interpretation: Confirms that the cyclase lesion raises outer-segment calcium in the intact retina, the step this node asserts.

Show evidence (1 reference)

PMID:15240799 SUPPORT Model Organism

"The enhanced activity of the cyclase in the dark increased cyclic nucleotide-gated channel activity and elevated the rod outer segment Ca2+ concentration in darkness"

Reports the calcium measurement behind this readout.

Show evidence (1 reference)

PMID:15240799 SUPPORT Model Organism

"we created transgenic mice that express GCAP1 with a Tyr99Cys substitution (Y99C GCAP1) found in human patients with a late-onset retinal dystrophy"

Establishes that the model carries the human founding disease allele, which is what makes it informative for this node.

Cone Photoreceptor Degeneration partially recapitulates fidelity: moderate Photoreceptors degenerate in these mice at a rate scaling with transgene expression, and do not degenerate in mice overexpressing wild-type GCAP1, isolating the variant as the cause.

Limitations: The mouse retina is rod-dominant, so the reported degeneration is predominantly of rods, whereas human GUCA1A disease is cone-first and cone-predominant. The model therefore supports the causal step from calcium overload to photoreceptor death without reproducing the cell-type selectivity that defines the human phenotype.

Readouts

Photoreceptor cell loss

Retinal photoreceptor counts across transgenic lines of differing expression level, compared with wild-type GCAP1 overexpressors.

Direction: INCREASED

Interpretation: Dose-dependent loss with the mutant transgene only, which separates the effect of the variant from the effect of overexpression.

Show evidence (1 reference)

PMID:15240799 SUPPORT Model Organism

"However, the photoreceptors in these mice degenerated, and the rate of the cell loss increased with the level of the transgene expression, unlike in transgenic mice that overexpressed normal GCAP1."

Reports the cell-loss measurement and the wild-type control behind this readout.

Show evidence (1 reference)

PMID:15240799 SUPPORT Model Organism

"These results provide the first direct evidence that a mutation linked to congenital blindness increases Ca2+ in the outer segment, which may trigger the apoptotic process."

States the authors' own claim that the model links the calcium rise to photoreceptor death, which is the claim this link makes.

Impaired Cone Light-Response Generation and Delayed Recovery fails to recapitulate fidelity: low Despite a measurable rise in dark outer-segment Ca2+, the rod photoresponse in these mice was largely unchanged, so the model does not reproduce the light-response failure seen on human cone-driven ERG.

Limitations: The negative result is a rod measurement in a rod-dominant retina, and cone light responses were not the readout, so it is evidence that the rod arm is spared rather than evidence against the human cone finding. This is why the corresponding human node is scoped to cones.

Readouts

Rod photoresponse amplitude and kinetics

Single-cell rod photoresponses recorded from Y99C transgenic retinas.

Direction: UNCHANGED

Interpretation: Dynamic Ca2+-dependent regulation of cGMP synthesis was preserved in rods despite the raised dark calcium.

Show evidence (1 reference)

PMID:15240799 SUPPORT Model Organism

"Surprisingly, there was little change in the rod photoresponse, indicating that dynamic Ca2+-dependent regulation of cGMP synthesis was preserved."

Reports the negative photoresponse result behind this readout.

Show evidence (1 reference)

PMID:15240799 SUPPORT Model Organism

"Surprisingly, there was little change in the rod photoresponse, indicating that dynamic Ca2+-dependent regulation of cGMP synthesis was preserved."

The authors report the preserved rod photoresponse as a surprising negative finding, which is the substance of this failure-to-recapitulate claim.

Show evidence (1 reference)

PMID:15240799 SUPPORT Model Organism

"we created transgenic mice that express GCAP1 with a Tyr99Cys substitution (Y99C GCAP1) found in human patients with a late-onset retinal dystrophy"

Establishes that this model expresses the human founding disease allele, which is what makes it informative for this disease.

GCAP1 RNAi knockdown rescue models

Two dominant GCAP1 retinal degeneration mouse lines used as a therapeutic test bed: an allele-specific Y99C line with a rapid phenotype and a non-allele-specific L151F line with a slow cone-rod dystrophy that the authors present as the closer match to human GCAP1 disease. Subretinal scAAV2/8 delivering GCAP1 shRNA was used to knock the transgene down.

Species

Mouse

Genotype

Transgenic bovine GCAP1(Y99C) and mouse GCAP1(L151F), treated with scAAV2/8 shRNA against GCAP1

Publication

PMID:24778606

Pathograph links

Cone Photoreceptor Degeneration rescues fidelity: moderate Knocking down mutant GCAP1 enhanced photoreceptor survival, delayed degeneration onset, and improved visual function in both lines, which is the interventional counterpart of the claim that GCAP1 gain of function drives the degeneration.

Limitations: Both lines are transgenic overexpressors rather than knock-ins, one expresses a bovine transgene, and the rescue is preclinical with no human trial. Photoreceptor survival in a rod-dominant mouse retina is not a direct measure of the cone survival that matters clinically.

Readouts

Photoreceptor survival after GCAP1 knockdown

Photoreceptor survival, degeneration onset, and visual function after subretinal scAAV2/8 shRNA delivery, compared with untreated eyes.

Direction: RESTORED

Interpretation: Removing the mutant gene product slows the degeneration, supporting the causal direction of this node.

Show evidence (1 reference)

PMID:24778606 SUPPORT Model Organism

"RNAi-mediated gene silencing enhanced photoreceptor survival, delayed onset of degeneration and improved visual function"

Reports the survival and function measurements behind this readout.

Show evidence (1 reference)

PMID:24778606 SUPPORT Model Organism

"The allele-specific model expresses transgenic bovine GCAP1(Y99C) establishing a rapid RP-like phenotype, whereas the nonallele-specific model expresses mouse GCAP1(L151F) producing a slowly progressing cone-rod dystrophy (CORD)."

Describes what the two models are and which one the authors regard as matching the human cone-rod dystrophy, which is what makes them informative for this node.

Show evidence (1 reference)

PMID:24778606 SUPPORT Model Organism

"The late onset GCAP1(L151F)-CORD mimics the dystrophy observed in human GCAP1-CORD patients."

The authors state which of the two lines they regard as matching human GCAP1 cone-rod dystrophy, which is the basis for treating these models as informative for this disease.

GUCA1A p.Arg120Leu zebrafish overexpression model

Zebrafish embryos injected with mutant human GUCA1A mRNA, with wild-type mRNA injected alone and co-injected as controls. Used to separate a toxic gain-of-function mechanism from a dominant-negative one.

Species

Zebrafish

Genotype

Transient overexpression of human GUCA1A mRNA carrying p.Arg120Leu

Publication

PMID:28125083

Pathograph links

Cone Photoreceptor Degeneration partially recapitulates fidelity: low Mutant-injected larvae lost cone inner-segment and outer-segment staining and cone cell-body signal, and co-injected wild-type mRNA did not rescue the loss, which is the behavior expected of a toxic gain-of-function allele rather than a haploinsufficiency.

Limitations: This is transient mRNA overexpression in a larval fish, not expression of a heterozygous allele from the endogenous locus, so the dosage is not physiological and the timescale is developmental rather than the adult degeneration seen in patients. Rod markers were lost as well as cone markers, which does not match the cone-predominant human phenotype. p.Arg120Leu is not among the alleles in the largest human cohort.

Readouts

Cone inner segment and outer segment staining

Peanut agglutinin lectin staining of cone inner and outer segments in retinal sections at 4 days postfertilization.

Direction: DECREASED

Interpretation: Loss of cone segment structure in mutant-injected larvae.

Show evidence (1 reference)

PMID:28125083 SUPPORT Model Organism

"the cone inner segment/OS, indicated by peanut agglutinin lectin staining, were significantly reduced or even vanished in larvae injected with GUCA1Ap.R120L"

Reports the cone staining measurement behind this readout.

Show evidence (1 reference)

PMID:28125083 SUPPORT Model Organism

"Thus, our findings revealed that photoreceptors are impaired by GUCA1A p.R120L in a toxic gain-of-function way."

The authors' own conclusion that the allele acts by toxic gain of function, which is what makes this model informative for a gain-of-function degeneration node.

Notes

The same study reached the opposite conclusion for a different allele: in the identical assay p.Asp100Glu was rescued by co-injected wild-type mRNA, which the authors read as dominant-negative rather than toxic gain of function. Not every pathogenic GUCA1A allele is assumed here to act by the constitutive-activation mechanism the pathograph models, and p.Asp100Glu is deliberately not listed among the variants in the genetic section.

Show evidence (1 reference)

PMID:28125083 SUPPORT Model Organism

"To test the hypothesis that p.R120L causes disease through a gain-of-function mechanism, we overexpressed WT (hereafter termed GUCA1AWT) or mutated human GUCA1A mRNA (GUCA1Ap.R120L) in zebrafish to characterize their relevant pathology."

States the design of the model and the question it was built to answer.

{ }

Source YAML

click to show

name: GUCA1A-Related Retinopathy
creation_date: "2026-08-25T10:00:00Z"
category: Mendelian
description: >-
  GUCA1A-related retinopathy is an autosomal dominant inherited retinal disease
  caused by heterozygous missense variants in GUCA1A, encoding guanylate
  cyclase-activating protein 1 (GCAP1), the principal calcium sensor that
  regulates retinal guanylate cyclase (RetGC1/RetGC2) activity during
  phototransduction recovery. Under normal dark-adapted conditions, high
  intracellular Ca2+ loads the EF-hand domains of GCAP1, switching it into a
  conformation that inhibits RetGC; as light exposure lowers Ca2+, GCAP1
  switches to an activating conformation that accelerates cGMP resynthesis.
  Pathogenic GUCA1A variants cluster in the EF-hand calcium-binding loops and
  lock GCAP1 into a constitutively activating conformation regardless of
  ambient Ca2+, producing chronically elevated cGMP, sustained opening of
  cyclic nucleotide-gated (CNG) channels, and toxic Ca2+ accumulation in
  photoreceptor outer segments. The founding and most recurrent variant is
  p.Tyr99Cys (Y99C), first described in 1998; the disease is genetically and
  clinically continuous with a spectrum from isolated cone dystrophy (COD3)
  to cone-rod dystrophy (CORD14), with cone photoreceptors affected earliest
  and most severely because GCAP1/RetGC-mediated recovery kinetics are more
  critical to cone light-response timing than to rods.
disease_term:
  preferred_term: GUCA1A-related retinopathy
  term:
    id: MONDO:0700376
    label: GUCA1A-related retinopathy
synonyms:
- Cone dystrophy 3
- COD3
- Cone-rod dystrophy 14
- CORD14
- GUCA1A-related cone dystrophy
- GUCA1A-related cone-rod dystrophy
- GCAP1-related retinopathy
parents:
- Inherited Retinal Dystrophy
- Cone-Rod Dystrophy
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0011193
      label: cone dystrophy 3
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >-
      Cone dystrophy 3 (COD3) is the historical cone-restricted presentation of
      GUCA1A-related retinopathy and a child term of MONDO:0700376.
  - term:
      id: MONDO:0800326
      label: cone-rod dystrophy 14
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >-
      Cone-rod dystrophy 14 (CORD14) is the child term for GUCA1A-related
      presentations with secondary rod involvement.
notes: >-
  Modeled as a single umbrella entity rather than forced has_subtypes: the
  largest reported cohort (Allon et al. 2025, PMID:39969478, 19 patients/14
  families) found the same variant class producing both cone-restricted and
  cone-rod/macular phenotypes, and genotype-phenotype correlation is by
  individual variant (e.g. p.Glu111Ala versus p.Leu84Phe) rather than by a
  clean COD-versus-CORD split. MONDO:0011193 (COD3) and MONDO:0800326 (CORD14)
  are the two child terms under MONDO:0700376 and are captured via
  mondo_mappings narrowMatch. GUCA1A is also one of several genes (with
  PRPH2, GUCY2D, CDHR1, ABCA4, TTLL5) that can produce a central areolar
  choroidal dystrophy (CACD)-spectrum maculopathy at the severe end of its
  phenotypic range; that distinct, etiologically heterogeneous clinical entity
  is separately curated at kb/disorders/Central_Areolar_Choroidal_Dystrophy.yaml
  and is not duplicated here.

inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Heterozygous gain-of-function missense variants in GUCA1A cause autosomal
    dominant GUCA1A-related retinopathy. Each child of an affected parent has
    a 50% chance of inheriting the pathogenic variant.
  evidence:
  - reference: PMID:9425234
    reference_title: "A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a mutation (Y99C) in guanylate cyclase activator 1A (GUCA1A), the gene for guanylate cyclase activating protein (GCAP1), in a family with autosomal dominant cone dystrophy."
    explanation: >-
      Payne et al. establish the founding GUCA1A Y99C mutation as the cause of
      autosomal dominant cone dystrophy in the original discovery pedigree.

prevalence:
- population: United States
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.4
  notes: >-
    Derived from a US series of 1000 consecutive inherited retinal disease
    cases carrying 7 GUCA1A cases, from which the authors extrapolated a
    US-wide prevalence of 1 in 247,143. That is 0.4 per 100,000, or about 4
    per million, which is the BAND_1_9_PER_1000000 class. The estimate is an
    extrapolation from a single referral cohort, not a population survey.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A US-based study of 1000 consecutive IRD cases found 7 cases with GUCA1A variants; the authors estimated a US-wide prevalence of 1 in 247,143 people."
    explanation: >-
      States both the observed case count and the extrapolated population
      prevalence figure this record converts.
- population: Inherited retinal disease clinic cohorts (US, UK, Spain, Germany, Japan, China)
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >-
    Across six published IRD cohorts, GUCA1A accounted for roughly 0.1% to
    0.7% of patients or families. The denominator here is an inherited
    retinal disease clinic population, not a general population, so no
    magnitude band applies and the record is deliberately left unbanded. The
    authors note the spread also reflects differing genetic testing
    strategies and whether the denominator counts all IRD patients or only
    those with a positive molecular diagnosis.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus, the prevalence in IRD cohorts appears to range from roughly 0.1% to 0.7%."
    explanation: >-
      Gives the cross-cohort range of the GUCA1A share of inherited retinal
      disease diagnoses.

pathophysiology:
- name: GCAP1 Loss of Calcium-Dependent Inhibitory Control
  conforms_to: "phototransduction_cascade_dysfunction#Phototransduction Cascade Component Defect"
  biological_scale: MOLECULAR
  description: >-
    Dominant missense variants in GUCA1A cluster in the EF-hand calcium-binding
    loops of GCAP1 (e.g. EF3 for the founding p.Tyr99Cys variant, EF4 for
    p.Asp144Gly), impairing the protein's ability to sense rising dark-adapted
    Ca2+ and switch into its RetGC-inhibiting conformation. The founding
    p.Tyr99Cys variant does not decrease GCAP1's ability to activate RetGC, but
    the resulting RetGC-GCAP1 complex remains active even at Ca2+
    concentrations above 1 microM, well into the physiological dark-adapted
    range, rather than being suppressed as normal GCAP1 would suppress it.
    Other variants (p.Asn104His, p.Leu176Phe, p.Asp144Gly) act through related
    biophysical mechanisms: impaired Ca2+ sensitivity, altered Mg2+/Ca2+
    exchange kinetics, or increased binding affinity for RetGC, all converging
    on loss of the normal Ca2+-dependent brake on cyclase activation.
  gene:
    preferred_term: GUCA1A
    modifier: GAIN_OF_FUNCTION
    term:
      id: hgnc:4678
      label: GUCA1A
  genetic_context:
    gene:
      preferred_term: GUCA1A
      term:
        id: hgnc:4678
        label: GUCA1A
    allele_type: MISSENSE
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    functional_impact_category: GAIN_OF_FUNCTION
    description: >-
      Monoallelic missense variants that leave GCAP1's capacity to activate
      RetGC intact and remove its Ca2+-dependent off-switch, so the variant
      acts by adding constitutive activation rather than by abolishing
      function.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  - preferred_term: retinal rod cell
    term:
      id: CL:0000604
      label: retinal rod cell
  biological_processes:
  - preferred_term: detection of calcium ion
    modifier: DECREASED
    term:
      id: GO:0005513
      label: detection of calcium ion
  evidence:
  - reference: PMID:9651312
    reference_title: "Constitutive activation of photoreceptor guanylate cyclase by Y99C mutant of GCAP-1. Possible role in causing human autosomal dominant cone degeneration."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The Y99C mutation does not decrease the ability of GCAP-1 to activate RetGC. However, RetGC stimulated by the Y99C GCAP-1 remains active even at Ca2+ concentration above 1 microM. Hence, the cyclase becomes constitutively active within the whole physiologically relevant range of free Ca2+ concentrations."
    explanation: >-
      Dizhoor et al. biochemically demonstrate that the Y99C GCAP1 mutant fails
      to lose its RetGC-activating conformation at high (dark-adapted) Ca2+,
      the direct molecular basis of loss of calcium-dependent inhibitory
      control.
  - reference: PMID:28025326
    reference_title: "Dysfunction of cGMP signalling in photoreceptors by a macular dystrophy-related mutation in the calcium sensor GCAP1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The mutant was less sensitive to changes in free Ca2+, resulting in a constitutively active form under physiological Ca2+-concentration, showed significantly higher activation rates than the wildtype (90-fold versus 20-fold) and interacted with an higher apparent affinity with its target guanylate cyclase."
    explanation: >-
      Vocke et al. show the L176F GCAP1 variant is biochemically less
      Ca2+-sensitive and binds RetGC with higher affinity, reproducing the
      same loss-of-calcium-control mechanism in a second, independently
      identified variant.
  - reference: PMID:30679166
    reference_title: "Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These result in persistent stimulation of RetGC, excess cGMP levels in the dark and photoreceptor apoptosis secondary to Ca2+ dysregulation."
    explanation: >-
      Gill et al. summarize the shared consequence of the GUCA1A
      gain-of-function alleles, tying the EF-hand lesion to persistent RetGC
      stimulation. Classified OTHER because this is a narrative review
      synthesizing published cohorts rather than reporting primary
      observations.
  downstream:
  - target: RetGC Constitutive Hyperactivity
    description: >-
      A GCAP1 that can no longer be switched off by rising dark-adapted Ca2+
      continues to drive RetGC catalytic activity regardless of the
      photoreceptor's light-adaptation state.

- name: RetGC Constitutive Hyperactivity
  conforms_to: "phototransduction_cascade_dysfunction#Loss of Outer-Segment cGMP and Calcium Set-Point Control"
  biological_scale: MOLECULAR
  description: >-
    Constitutively activating mutant GCAP1 continues to stimulate retinal
    guanylate cyclase (RetGC1 and, for some variants, also RetGC2) even at
    Ca2+ concentrations characteristic of the dark-adapted state, when wild-type
    GCAP1 would normally suppress the enzyme. This produces chronically
    elevated cGMP synthesis that is no longer coupled to the light-dependent
    Ca2+ signal, independent of the ambient light state.
  gene:
    preferred_term: GUCA1A
    modifier: GAIN_OF_FUNCTION
    term:
      id: hgnc:4678
      label: GUCA1A
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: cGMP biosynthetic process
    modifier: INCREASED
    term:
      id: GO:0006182
      label: cGMP biosynthetic process
  evidence:
  - reference: PMID:34639157
    reference_title: "A Novel GUCA1A Variant Associated with Cone Dystrophy Alters cGMP Signaling in Photoreceptors by Strongly Interacting with and Hyperactivating Retinal Guanylate Cyclase."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The altered interaction with GC would cause hyper-activity of the enzyme at both low and high Ca2+ levels, which would ultimately lead to toxic accumulation of cGMP and Ca2+ in the photoreceptor outer segment, thus triggering cell death."
    explanation: >-
      Biasi et al. directly link the N104H GCAP1 variant's hyperactivation of
      guanylate cyclase to downstream toxic cGMP/Ca2+ accumulation, connecting
      the enzymatic hyperactivity node to the downstream calcium overload node.
  - reference: PMID:15240799
    reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Y99C GCAP1 shifted the Ca2+ sensitivity of the guanylyl cyclase in photoreceptors, keeping it partially active at 250 nM free Ca2+, the normal resting Ca2+ concentration in darkness."
    explanation: >-
      Olshevskaya et al. show in vivo that the Y99C transgene leaves the
      cyclase active at the resting dark Ca2+ concentration, confirming in a
      whole retina the set-point failure demonstrated biochemically.
  downstream:
  - target: Sustained CNG Channel Opening and Outer-Segment Calcium Overload
    description: >-
      Chronically elevated cGMP keeps cyclic nucleotide-gated (CNG) channels
      open independent of the light state, producing sustained Ca2+/Na+
      influx into the photoreceptor outer segment.
  - target: Impaired Cone Light-Response Generation and Delayed Recovery
    description: >-
      A cyclase that is no longer gated by the light-driven fall in Ca2+
      cannot shape the cone photoresponse, degrading the amplitude and the
      timing of the cone-driven light response.
  - target: Abnormal Photoreceptor-to-ON-Bipolar Synaptic Transmission
    description: >-
      In a minority of patients the dysregulated GCAP1-cyclase complex
      propagates past the outer segment to the photoreceptor synaptic
      terminal.

- name: Sustained CNG Channel Opening and Outer-Segment Calcium Overload
  conforms_to: "phototransduction_cascade_dysfunction#cGMP and Calcium Overload Handoff to Photoreceptor Degeneration"
  biological_scale: CELLULAR
  description: >-
    Chronically elevated cGMP holds cyclic nucleotide-gated channels open
    independent of the light state, so Ca2+ and Na+ enter the outer segment
    continuously and free Ca2+ rises above its normal dark level. This is the
    branch point at which a phototransduction set-point lesion becomes a
    degenerative rather than a stationary disease.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: calcium ion transmembrane import into cytosol
    modifier: INCREASED
    term:
      id: GO:0097553
      label: calcium ion transmembrane import into cytosol
  evidence:
  - reference: PMID:15240799
    reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The enhanced activity of the cyclase in the dark increased cyclic nucleotide-gated channel activity and elevated the rod outer segment Ca2+ concentration in darkness"
    explanation: >-
      Olshevskaya et al. measured the outer-segment Ca2+ rise directly in the
      Y99C transgenic retina, establishing that the channel opening and the
      calcium overload are real consequences of the cyclase lesion and not
      only an inference from biochemistry.
  - reference: PMID:34639157
    reference_title: "A Novel GUCA1A Variant Associated with Cone Dystrophy Alters cGMP Signaling in Photoreceptors by Strongly Interacting with and Hyperactivating Retinal Guanylate Cyclase."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The altered interaction with GC would cause hyper-activity of the enzyme at both low and high Ca2+ levels, which would ultimately lead to toxic accumulation of cGMP and Ca2+ in the photoreceptor outer segment, thus triggering cell death."
    explanation: >-
      Biasi et al. name toxic cGMP and Ca2+ accumulation in the outer segment
      as the step between cyclase hyperactivity and photoreceptor death.
  downstream:
  - target: Cone Photoreceptor Degeneration
    description: >-
      Sustained calcium and cGMP elevation in the outer segment triggers
      photoreceptor cell death.
  - target: Variable Rod Photoreceptor Involvement
    description: >-
      GCAP1 is expressed in rods as well as cones, so the same set-point
      lesion can reach the rod population, later and in a minority of
      patients.
  notes: >-
    The module node this conforms to instructs a conforming disorder to
    declare conformance to photoreceptor_degeneration as well. That module is
    not wired here on purpose: its chain is rod-first and cell-autonomous in
    rods, with cone loss modeled as a non-cell-autonomous consequence of rod
    elimination. GUCA1A disease runs the other way, with cones affected
    earliest and most severely because GCAP1 expression is higher in cones,
    so a conformance claim against those rod-first nodes would assert a
    sequence this disease does not follow.

- name: Impaired Cone Light-Response Generation and Delayed Recovery
  conforms_to: "phototransduction_cascade_dysfunction#Failure of Photoreceptor Light-Response Generation or Timely Recovery"
  biological_scale: CELLULAR
  description: >-
    Loss of the Ca2+-gated cyclase brake degrades the cone light response
    itself, separately from the degenerative arm. Cone-driven full-field ERG
    amplitudes are reduced in most affected patients, and in the most severely
    affected the 30-Hz flicker response is also delayed, which is the timing
    signature of a recovery defect rather than a pure amplitude loss.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: regulation of opsin-mediated signaling pathway
    modifier: DECREASED
    term:
      id: GO:0022400
      label: regulation of opsin-mediated signaling pathway
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ten of 13 subjects had subnormal LA 30-Hz or LA 3 (single-flash) ERGs"
    explanation: >-
      Allon et al. quantify reduced cone-driven light-adapted ERG responses in
      the majority of tested patients, the functional readout of failed cone
      light-response generation.
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "there was an additional LA 30-Hz ERG delay in the 5 with the smallest LA responses"
    explanation: >-
      The flicker peak-time delay in the most severely affected patients is
      the timing abnormality that distinguishes a recovery defect from a
      simple loss of responding cones.
  downstream:
  - target: Abnormal electroretinogram
    description: >-
      Reduced and delayed cone-driven responses are what the clinical
      full-field and pattern ERG records.
  notes: >-
    Scoped to cones on purpose. The Y99C transgenic mouse showed little change
    in the rod photoresponse despite a measurable rise in dark outer-segment
    Ca2+ (PMID:15240799), so a general claim of failed photoreceptor
    light-response generation across both photoreceptor classes is not
    supported. Human rod-driven dark-adapted ERGs were normal in all but one
    tested patient in the Allon cohort, and that exception was attributed to
    incomplete mydriasis.

- name: Abnormal Photoreceptor-to-ON-Bipolar Synaptic Transmission
  biological_scale: CELLULAR
  description: >-
    In some patients the dysregulated GCAP1-cyclase complex disturbs signaling
    at the photoreceptor synaptic terminal rather than only in the outer
    segment, producing an attenuated b-wave and an electronegative ERG
    waveform that indicate an ON-pathway transmission defect.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  - preferred_term: retinal bipolar neuron
    term:
      id: CL:0000748
      label: retinal bipolar neuron
  biological_processes:
  - preferred_term: synaptic transmission, glutamatergic
    modifier: DECREASED
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
  evidence:
  - reference: PMID:33919796
    reference_title: "Impaired Ca(2+) Sensitivity of a Novel GCAP1 Variant Causes Cone Dystrophy and Leads to Abnormal Synaptic Transmission Between Photoreceptors and Bipolar Cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the abnormal electroretinogram recorded in this patient also suggested that the dysregulation of the GCAP1-cyclase complex further propagates to the synaptic terminal, thereby altering the ON-pathway related to the b-wave generation"
    explanation: >-
      Marino et al. report ERG evidence in a patient carrying a double GCAP1
      substitution (N104K/G105R) that dysregulated GCAP1-RetGC signaling also
      disturbs synaptic transmission to ON-bipolar cells.
  - reference: PMID:33919796
    reference_title: "Impaired Ca(2+) Sensitivity of a Novel GCAP1 Variant Causes Cone Dystrophy and Leads to Abnormal Synaptic Transmission Between Photoreceptors and Bipolar Cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Severe alterations of the electroretinogram were observed under both scotopic and photopic conditions, with a negative pattern and abnormally attenuated b-wave component."
    explanation: >-
      The negative ERG waveform with attenuated b-wave is the specific
      electrophysiological signature of inner-retinal transmission failure
      rather than outer-segment loss alone.
  downstream:
  - target: Abnormal electroretinogram
    description: >-
      The ON-pathway transmission defect appears clinically as a negative ERG
      waveform with an attenuated b-wave.
  notes: >-
    Kept as its own node rather than folded into the degeneration chain
    because the evidence for it is a single reported patient with a double
    p.Asn104Lys/p.Gly105Arg substitution, and a negative or electronegative
    waveform was seen in only a minority of the Allon cohort. It is a
    variant-associated branch of the disease, not a step every patient passes
    through.

- name: Cone Photoreceptor Degeneration
  biological_scale: CELLULAR
  description: >-
    Persistent calcium and cGMP elevation triggers photoreceptor cell death.
    Cones bear the earliest and most severe toxicity because GCAP1 expression
    is higher in cones and cone recovery kinetics depend on it more heavily,
    with later, more variable rod and macular RPE involvement depending on the
    specific variant.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  - preferred_term: photoreceptor cell maintenance
    modifier: DECREASED
    term:
      id: GO:0045494
      label: photoreceptor cell maintenance
  evidence:
  - reference: PMID:15240799
    reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "However, the photoreceptors in these mice degenerated, and the rate of the cell loss increased with the level of the transgene expression, unlike in transgenic mice that overexpressed normal GCAP1."
    explanation: >-
      Dose-dependent photoreceptor loss with the mutant but not the wild-type
      transgene establishes that degeneration follows from the variant rather
      than from GCAP1 overexpression as such.
  - reference: PMID:30679166
    reference_title: "Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The relative preservation of rod responses in most GUCA1A-associated progressive retinal dystrophies is attributed to greater GCAP1 expression in cones."
    explanation: >-
      Gill et al. give the reason cones are affected first, which is the
      claim this node makes about the cell-type selectivity of the
      degeneration. Classified OTHER because this is a narrative review.
  downstream:
  - target: Progressive visual loss
    description: >-
      Loss of central cones is what patients experience as progressive decline
      in central visual acuity.
  - target: Color vision defect
    description: >-
      Cone loss removes the substrate for color discrimination, which is why
      dyschromatopsia is the commonest presenting symptom.
  - target: Macular atrophy
    description: >-
      Degeneration of the central cone population appears structurally as
      ellipsoid-zone disruption and then macular atrophy on OCT.
  - target: Photophobia
    description: >-
      A degenerating and dysfunctional cone population underlies the light
      sensitivity reported by most affected patients.
  - target: Central scotoma
    description: >-
      Loss of the central cone population produces the central and
      paracentral field defects found on perimetry.
  - target: Reduced visual acuity
    description: >-
      Loss of the central cone population is what the measured logMAR acuity
      records at any one visit.

- name: Variable Rod Photoreceptor Involvement
  biological_scale: CELLULAR
  description: >-
    GCAP1 is expressed in rods as well as cones, so the rod population is not
    immune to the same cGMP and calcium set-point lesion. Rod involvement is
    the exception rather than the rule: dark-adapted rod-specific ERGs were
    normal in almost every tested patient, and peripheral pigmentary change
    appeared in 2 of 19. Where it occurs it marks the cone-rod end of the
    phenotypic range, not a conversion to a rod-first disease.
  cell_types:
  - preferred_term: retinal rod cell
    term:
      id: CL:0000604
      label: retinal rod cell
  biological_processes:
  - preferred_term: photoreceptor cell maintenance
    modifier: DECREASED
    term:
      id: GO:0045494
      label: photoreceptor cell maintenance
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the latter patient, the nature and progression of symptoms were still more in keeping with a cone-rod, rather than a rod-cone, dystrophy, and other family members did not show the pigmentary changes."
    explanation: >-
      Even in the patient with peripheral pigmentary change, the course stayed
      cone-rod. This is the evidence for scoping this node as variable
      involvement rather than as a rod-degeneration arm.
  - reference: PMID:30679166
    reference_title: "Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The relative preservation of rod responses in most GUCA1A-associated progressive retinal dystrophies is attributed to greater GCAP1 expression in cones."
    explanation: >-
      Gives the reason rods are relatively spared, which is the same claim
      this node makes from the other side: rods carry the lesion but at lower
      GCAP1 dose. Classified OTHER because this is a narrative review.
  downstream:
  - target: Peripheral pigmentary retinopathy
    description: >-
      Rod and outer-retinal involvement at the periphery appears on
      ultra-widefield imaging as pigment spicules.
  - target: Nyctalopia
    description: >-
      Rod dysfunction, where it occurs, is what a patient reports as night
      blindness.

phenotypes:
- category: Ophthalmological
  name: Progressive visual loss
  frequency: VERY_FREQUENT
  description: >-
    Progressive decline in central visual acuity is the dominant presenting
    and progressive feature of GUCA1A-related retinopathy, correlating with
    patient age across longitudinal follow-up. Central vision deficits were
    reported by 17 of 19 patients (89.5%) in the largest cohort.
  phenotype_term:
    preferred_term: Progressive visual loss
    term:
      id: HP:0000529
      label: Progressive visual loss
    clinical_course: PROGRESSIVE
    onset:
      onset_category: YOUNG_ADULT
      mean_age_years: 23.0
      min_age_years: 5.0
      max_age_years: 74.0
      notes: >-
        Mean age at symptom onset 23 years (SD 17), range 5 to 74, across the
        19-patient Allon cohort. The category is set on the mean; the range
        spans childhood to old age, and this wide spread is itself a
        characteristic of the disease rather than a measurement artifact.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most had progressive visual loss and electrophysiologic evidence of cone dystrophy."
    explanation: >-
      Allon et al. report progressive visual loss as the predominant clinical
      course in the largest reported GUCA1A cohort (19 patients, 14 families).
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean (SD) age of onset of symptoms was 23 (17) years (range, 5–74 years)."
    explanation: >-
      Source for the onset descriptor: mean age of symptom onset and its full
      reported range in the same cohort.

- category: Ophthalmological
  name: Reduced visual acuity
  frequency: VERY_FREQUENT
  description: >-
    Visual acuity at presentation is variable but declines with age and can
    range from near-normal to no light perception in advanced disease;
    logMAR acuity correlates with patient age across longitudinal follow-up.
  phenotype_term:
    preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
  phenotype_contexts:
  - sex: MALE
    notes: >-
      In a mixed-effects model across 144 visits, male sex was associated with
      worse visual acuity independent of age. The cohort was 68.4% male and
      the authors treat the association as provisional.
    evidence:
    - reference: PMID:39969478
      reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "male sex was associated with worse acuity (P = 0.023)"
      explanation: >-
        Reports sex as a modifier of acuity severity within the GUCA1A cohort.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acuities ranged from 0.00 logMAR to no light perception."
    explanation: >-
      Allon et al. document the full range of visual acuity severity observed
      across the GUCA1A cohort, from near-normal to no light perception.

- category: Ophthalmological
  name: Color vision defect
  frequency: VERY_FREQUENT
  description: >-
    Dyschromatopsia is the characteristic early feature of GUCA1A-related
    retinopathy, reflecting the cone-predominant nature of the underlying
    photoreceptor dysfunction. It affected 16 of 19 patients (84.2%) over
    follow-up and was the presenting complaint in 13 (68.4%).
  phenotype_term:
    preferred_term: Color vision defect
    term:
      id: HP:0000551
      label: Color vision defect
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, across the entire duration of follow-up, 17 patients (89.5%) reported central vision deficits, 16 patients (84.2%) described color vision deficits, 15 (78.9%) reported some degree of photophobia"
    explanation: >-
      84.2% of the cohort described color vision deficits, which places the
      frequency in the VERY_FREQUENT band (80-99%).
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirteen patients (68.4%) described poor color discrimination as their initial symptom"
    explanation: >-
      Color vision impairment is also the commonest presenting symptom, which
      is why it is treated as the early feature of the disease.

- category: Ophthalmological
  name: Photophobia
  frequency: FREQUENT
  description: >-
    Light sensitivity is a typical symptom of GUCA1A-related cone and cone-rod
    dystrophy, reported by 15 of 19 patients (78.9%) in the largest cohort.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, across the entire duration of follow-up, 17 patients (89.5%) reported central vision deficits, 16 patients (84.2%) described color vision deficits, 15 (78.9%) reported some degree of photophobia"
    explanation: >-
      78.9% of the GUCA1A cohort reported photophobia, which sets the
      FREQUENT band (30-79%) just below the VERY_FREQUENT threshold.
  - reference: PMID:30679166
    reference_title: "Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These disorders typically present with progressive loss of central vision, colour vision disturbance and photophobia."
    explanation: >-
      Supporting class-level characterization of photophobia as a typical
      presenting feature of progressive cone and cone-rod dystrophies, of
      which GUCA1A is one of the four commonest causes. Classified OTHER
      because this is a narrative review, and it is a second item behind the
      GUCA1A-specific figure rather than the source of the frequency band.

- category: Electrophysiological
  name: Abnormal electroretinogram
  frequency: VERY_FREQUENT
  description: >-
    Electrophysiology in GUCA1A-related retinopathy is consistent with cone
    dystrophy in most patients, with a subset showing a macular dystrophy
    pattern; occasional patients show additional abnormalities in the
    ON-pathway b-wave component suggesting a synaptic transmission component.
  phenotype_term:
    preferred_term: Abnormal electroretinogram
    term:
      id: HP:0000512
      label: Abnormal electroretinogram
  reports_on:
  - target: RetGC Constitutive Hyperactivity
    relationship: READOUT_OF
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Full-field and pattern ERG capture the functional consequence of
      dysregulated cGMP/Ca2+ signaling in cone (and later rod) photoreceptors.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Electrophysiology (n = 13) was consistent with cone dystrophy (n = 11) or macular dystrophy (n = 2)."
    explanation: >-
      Allon et al. report electrophysiological findings consistent with cone
      dystrophy in the large majority of tested patients in the GUCA1A cohort.
  - reference: PMID:30679166
    reference_title: "Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ERG studies characteristically show reduced cone single-flash and flicker amplitudes with a normal implicit time"
    explanation: >-
      Describes the characteristic GUCA1A ERG signature. Classified OTHER
      because this is a narrative review. Note that the Allon cohort did find
      a flicker peak-time delay in its five most severely affected patients,
      so the normal implicit time described here holds for milder disease and
      is not universal.

- category: Ophthalmological
  name: Macular atrophy
  frequency: VERY_FREQUENT
  description: >-
    Maculopathy was present on OCT in every patient in the largest cohort.
    Imaging shows progressive irregularity of the central ellipsoid zone,
    then partial disruption, then complete loss of the layer, which is the
    structural correlate of central cone photoreceptor degeneration.
  phenotype_term:
    preferred_term: Macular atrophy
    term:
      id: HP:0007401
      label: Macular atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Maculopathy was evident in all individuals on OCT imaging."
    explanation: >-
      Structural macular involvement was universal (19/19) on OCT, which sets
      the VERY_FREQUENT band. The macular-dystrophy ERG pattern seen in 2 of
      13 tested patients is a separate, rarer electrophysiological finding
      and is recorded on the electroretinogram phenotype, not here.
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Optical coherence tomography showed irregularity and then loss of the central ellipsoid zone."
    explanation: >-
      Documents the progressive structural sequence on OCT underlying the
      atrophy.

- category: Ophthalmological
  name: Central scotoma
  frequency: OCCASIONAL
  description: >-
    Perimetry, performed in a minority of patients, showed central and
    paracentral field defects matching the central cone loss seen on imaging.
  phenotype_term:
    preferred_term: Central scotoma
    term:
      id: HP:0000603
      label: Central scotoma
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Visual field tests, where performed (four patients), demonstrated central and paracentral scotomas."
    explanation: >-
      Central and paracentral scotomas were found in all four patients who
      underwent perimetry. The frequency band is set on the 4 of 19 who were
      tested rather than on the 4 of 4 who were positive, because the cohort
      denominator is what the band describes and the untested patients are
      unknown rather than negative.

- category: Ophthalmological
  name: Peripheral pigmentary retinopathy
  frequency: OCCASIONAL
  description: >-
    Peripheral pigment spicules were seen in 2 of 19 patients, one carrying
    p.Tyr99Cys and one p.Glu111Ala. Even in those patients the symptom course
    remained cone-rod rather than rod-cone, so the finding marks the severe
    end of the GUCA1A range and not a separate retinitis pigmentosa phenotype.
  phenotype_term:
    preferred_term: Spicular pigmentation of the retina
    term:
      id: HP:0007737
      label: Spicular pigmentation of the retina
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Peripheral involvement with pigment spicules was noted in two individuals"
    explanation: >-
      2 of 19 patients (10.5%) had peripheral pigmentary change, which places
      the frequency in the OCCASIONAL band (5-29%).

- category: Ophthalmological
  name: Nyctalopia
  frequency: OCCASIONAL
  description: >-
    Night blindness is uncommon in GUCA1A-related retinopathy and was reported
    by a single patient in the largest cohort, consistent with the relative
    preservation of rod function in this disease.
  phenotype_term:
    preferred_term: Nyctalopia
    term:
      id: HP:0000662
      label: Nyctalopia
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "1 patient (IX-l) noted nyctalopia (5.3%)"
    explanation: >-
      One of 19 patients (5.3%) reported nyctalopia, which falls in the
      OCCASIONAL band (5-29%) at its lower edge. The band rests on a single
      patient in a 19-patient series and should be revisited against a larger
      cohort.

genetic:
- name: GUCA1A pathogenic variants
  gene_term:
    preferred_term: GUCA1A
    term:
      id: hgnc:4678
      label: GUCA1A
  association: Causative
  features: >-
    Heterozygous missense variants in GUCA1A, encoding guanylate cyclase
    activating protein 1 (GCAP1), cause autosomal dominant GUCA1A-related
    retinopathy. The founding and most recurrent variant is p.Tyr99Cys
    (Y99C), found in 10 of 14 families in the largest reported cohort; other
    reported pathogenic variants include p.Leu84Phe, p.Ile107Thr,
    p.Glu111Ala, p.Leu176Phe, p.Asp144Gly, and p.Asn104His, most clustering
    in or near the EF-hand calcium-binding loops of GCAP1. Emerging
    genotype-phenotype correlations include p.Glu111Ala associated with
    worse visual acuity than the common p.Tyr99Cys variant, p.Leu84Phe
    associated with younger age and earlier-onset visual loss, and
    p.Ile107Thr associated with later presentation and milder acuity
    reduction.
  inheritance:
  - name: Autosomal dominant
    evidence:
    - reference: PMID:9425234
      reference_title: "A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We report a mutation (Y99C) in guanylate cyclase activator 1A (GUCA1A), the gene for guanylate cyclase activating protein (GCAP1), in a family with autosomal dominant cone dystrophy."
      explanation: >-
        The founding GUCA1A discovery pedigree establishes autosomal dominant
        inheritance of GUCA1A-related cone dystrophy.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nineteen patients (14 families), with five different variants, were included: p.(Tyr99Cys) in 10 families and p.(Leu84Phe), p.(Ile107Thr), p.(Glu111Ala), and p.(leu176Phe) in 1 family each."
    explanation: >-
      Allon et al. document the variant spectrum and relative frequency of
      p.Tyr99Cys versus other GUCA1A variants in the largest reported cohort.
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared with the common p.(Tyr99Cys) variant, patients with p.(Glu111Ala) (n = 2) had worse vision; those with p.(Leu84Phe) (n = 3) were younger with earlier-onset visual loss. Patients with p.(Ile107Thr) (n = 2) showed later presentation, with milder acuity reduction."
    explanation: >-
      Allon et al. report preliminary genotype-phenotype correlations among
      the reported GUCA1A variants.
  - reference: PMID:15953638
    reference_title: "Mutation in the gene GUCA1A, encoding guanylate cyclase-activating protein 1, causes cone, cone-rod, and macular dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is the first report of this mutation also causing both cone-rod dystrophy and isolated macular dysfunction."
    explanation: >-
      Michaelides et al. found the single p.Tyr99Cys allele producing cone
      dystrophy, cone-rod dystrophy, and isolated macular dysfunction within
      one family. This is the direct evidence for modeling the disease as one
      umbrella entity rather than partitioning it into COD and CORD subtypes.
  - reference: PMID:15953638
    reference_title: "Mutation in the gene GUCA1A, encoding guanylate cyclase-activating protein 1, causes cone, cone-rod, and macular dystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The phenotypic variation described here exemplifies the intrafamilial heterogeneity of retinal dysfunction that can be observed in persons harboring the same mutation and chromosomal segment."
    explanation: >-
      States that the variability is intrafamilial, so it cannot be explained
      by genetic background differences between families and is not a
      genotype-driven split.

progression:
- phase: Symptomatic onset
  age_range: Second to third decade, with a reported range from age 5 to 74
  notes: >-
    Onset is typically in the second or third decade, most often as impaired
    color discrimination or loss of central vision. The mean age at symptom
    onset across the largest cohort was 23 years, but the range was wide and
    a minority present in childhood or after the sixth decade.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean (SD) age of onset of symptoms was 23 (17) years (range, 5–74 years)."
    explanation: >-
      Gives the mean and range of symptom onset in the 19-patient cohort.
  - reference: PMID:30679166
    reference_title: "Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Symptomatic onset usually occurs between the second and third decade with reduced central vision, photophobia and generalised dyschromatopsia."
    explanation: >-
      Independent characterization of the typical decade of onset and its
      presenting symptoms. Classified OTHER because this is a narrative
      review.
- phase: Gradual acuity decline
  age_range: Across adult follow-up
  notes: >-
    Visual acuity worsens with age at roughly 0.20 logMAR per decade, fitted
    across 144 patient visits in a mixed-effects model. The decline is
    gradual and highly symmetric between eyes, and vision may remain
    relatively preserved beyond the seventh decade in some patients.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it corresponded roughly to a worsening of approximately 0.20 logMAR per decade"
    explanation: >-
      Quantifies the rate of visual acuity decline in the largest cohort.
- phase: Structural macular progression
  age_range: Tracks acuity rather than age alone
  notes: >-
    OCT changes begin as mild ellipsoid-zone irregularity, advance to partial
    disruption of the layer as acuity falls toward 0.3 logMAR, and reach more
    complete loss of the photoreceptor layer years later once acuity falls
    below 0.7 logMAR, with outer nuclear layer and RPE involvement following.
    The staging tracks visual acuity more closely than chronological age: the
    cohort mean age was similar at the partial-disruption and complete-loss
    stages, and the reported age ranges for the two overlap.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to the mild EZ irregularity typically observed in the early stages of the disease, partial EZ disruption was also observed as the disease progressed and visual acuity levels reached approximately 0.3 logMAR. More complete loss of the photoreceptor layer was subsequently noted years later when visual acuity fell below 0.7 logMAR."
    explanation: >-
      Ties the two structural stages to the acuity levels at which they
      appear, which is how the cohort stages structural progression.
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The changes observed on OCT scans begin with mild EZ irregularity, progressing to atrophy affecting outer retinal layers, including the outer nuclear layer, and RPE irregularity."
    explanation: >-
      States the sequence of retinal layers involved as the maculopathy
      advances.

diagnosis:
- name: Molecular genetic testing
  diagnosis_term:
    preferred_term: Genetic Testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    Targeted Sanger sequencing, gene-panel sequencing, or exome/genome
    sequencing establishes the diagnosis. Variants are classified by ACMG
    criteria and annotated against the MANE select GUCA1A transcript
    NM_001384910.1. Molecular confirmation matters because the clinical
    picture overlaps other dominant cone and cone-rod dystrophies, and
    because a peripheral pigmentary phenotype should prompt consideration of
    alternative genetic causes.
  results: >-
    Confirms a heterozygous pathogenic or likely pathogenic GUCA1A missense
    variant, most often p.Tyr99Cys, and enables cascade testing of relatives.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Variant classification ascribing likely pathogenicity was performed in accordance with American College of Medical Genetics and Genomics (ACMG) guidelines."
    explanation: >-
      Documents the variant-classification standard applied in the reference
      cohort.
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Variants were annotated in relation to the most biologically relevant MANE select GUCA1A transcript NM_001384910.1."
    explanation: >-
      Names the reference transcript against which GUCA1A variants should be
      reported.
- name: Multimodal retinal imaging
  diagnosis_term:
    preferred_term: Optical Coherence Tomography
    term:
      id: NCIT:C20828
      label: Optical Coherence Tomography
  description: >-
    Spectral-domain OCT, fundus autofluorescence, and ultra-widefield
    pseudocolor fundus photography together stage the maculopathy. Fundus
    autofluorescence is the most sensitive of the three for early macular
    involvement, and ultra-widefield imaging is what detects the uncommon
    peripheral pigmentary change.
  results: >-
    OCT shows ellipsoid-zone irregularity progressing to partial then
    complete loss, with an optical gap between the neurosensory retina and
    the RPE at early stages; autofluorescence shows macular involvement that
    may precede any visible fundus change.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fundus autofluorescence demonstrated high sensitivity in detecting maculopathy and in some cases was able to identify macular involvement before findings were apparent on clinical examination or color or pseudocolor fundus images, although the OCT was usually abnormal."
    explanation: >-
      Establishes the relative sensitivity of autofluorescence and OCT for
      early macular involvement in this disease.
- name: Visual electrophysiology
  diagnosis_term:
    preferred_term: Retinal Examination
    term:
      id: NCIT:C101217
      label: Retinal Examination
  description: >-
    ISCEV-standard full-field and pattern electroretinography separate
    generalized cone-system dysfunction from macular-only disease and
    quantify severity. Pattern ERG P50 measures macular function; full-field
    light-adapted responses measure generalized cone function; dark-adapted
    responses test the rod system, which is usually spared.
  results: >-
    Most patients show a cone dystrophy pattern with reduced light-adapted
    responses; a minority show a macular dystrophy pattern with normal
    full-field ERGs. A negative waveform with attenuated b-wave points to the
    ON-pathway transmission variant of the disease.
  evidence:
  - reference: PMID:39969478
    reference_title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ERG findings were consistent with cone dystrophy in 11 subjects and with macular dystrophy in 2 cases"
    explanation: >-
      Shows how the ERG separates the generalized cone-dystrophy pattern from
      the macular-restricted pattern in this cohort.

animal_models:
- name: Y99C GCAP1 transgenic mouse
  species: Mouse
  genotype: Transgenic expression of GCAP1 carrying the Tyr99Cys substitution
  publication: PMID:15240799
  description: >-
    Transgenic mice expressing the human disease allele Y99C GCAP1, generated
    in several lines with differing transgene expression levels. The model
    reproduces the molecular lesion, the dark-state calcium elevation, and
    dose-dependent photoreceptor degeneration.
  evidence:
  - reference: PMID:15240799
    reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we created transgenic mice that express GCAP1 with a Tyr99Cys substitution (Y99C GCAP1) found in human patients with a late-onset retinal dystrophy"
    explanation: >-
      Establishes that this model expresses the human founding disease allele,
      which is what makes it informative for this disease.
  modeled_mechanisms:
  - target: Sustained CNG Channel Opening and Outer-Segment Calcium Overload
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Direct in vivo measurement of elevated outer-segment free Ca2+ in
      darkness, with increased CNG channel activity, in an animal carrying the
      human founding variant.
    limitations: >-
      Measurements were made in rod outer segments, whereas human disease is
      cone-predominant, and the transgene is overexpressed rather than
      expressed from the endogenous locus. Severity tracks transgene dose, so
      the rate of degeneration in any one line is not a model of the human
      rate.
    readouts:
    - name: Rod outer segment free calcium concentration in darkness
      target: Sustained CNG Channel Opening and Outer-Segment Calcium Overload
      description: >-
        Free Ca2+ in dark-adapted rod outer segments, measured with fluo-5F
        and laser spot microscopy.
      direction: INCREASED
      interpretation: >-
        Confirms that the cyclase lesion raises outer-segment calcium in the
        intact retina, the step this node asserts.
      evidence:
      - reference: PMID:15240799
        reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The enhanced activity of the cyclase in the dark increased cyclic nucleotide-gated channel activity and elevated the rod outer segment Ca2+ concentration in darkness"
        explanation: >-
          Reports the calcium measurement behind this readout.
    evidence:
    - reference: PMID:15240799
      reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "we created transgenic mice that express GCAP1 with a Tyr99Cys substitution (Y99C GCAP1) found in human patients with a late-onset retinal dystrophy"
      explanation: >-
        Establishes that the model carries the human founding disease allele,
        which is what makes it informative for this node.
  - target: Cone Photoreceptor Degeneration
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Photoreceptors degenerate in these mice at a rate scaling with transgene
      expression, and do not degenerate in mice overexpressing wild-type
      GCAP1, isolating the variant as the cause.
    limitations: >-
      The mouse retina is rod-dominant, so the reported degeneration is
      predominantly of rods, whereas human GUCA1A disease is cone-first and
      cone-predominant. The model therefore supports the causal step from
      calcium overload to photoreceptor death without reproducing the
      cell-type selectivity that defines the human phenotype.
    readouts:
    - name: Photoreceptor cell loss
      target: Cone Photoreceptor Degeneration
      description: >-
        Retinal photoreceptor counts across transgenic lines of differing
        expression level, compared with wild-type GCAP1 overexpressors.
      direction: INCREASED
      interpretation: >-
        Dose-dependent loss with the mutant transgene only, which separates
        the effect of the variant from the effect of overexpression.
      evidence:
      - reference: PMID:15240799
        reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "However, the photoreceptors in these mice degenerated, and the rate of the cell loss increased with the level of the transgene expression, unlike in transgenic mice that overexpressed normal GCAP1."
        explanation: >-
          Reports the cell-loss measurement and the wild-type control behind
          this readout.
    evidence:
    - reference: PMID:15240799
      reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These results provide the first direct evidence that a mutation linked to congenital blindness increases Ca2+ in the outer segment, which may trigger the apoptotic process."
      explanation: >-
        States the authors' own claim that the model links the calcium rise to
        photoreceptor death, which is the claim this link makes.
  - target: Impaired Cone Light-Response Generation and Delayed Recovery
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      Despite a measurable rise in dark outer-segment Ca2+, the rod
      photoresponse in these mice was largely unchanged, so the model does not
      reproduce the light-response failure seen on human cone-driven ERG.
    limitations: >-
      The negative result is a rod measurement in a rod-dominant retina, and
      cone light responses were not the readout, so it is evidence that the
      rod arm is spared rather than evidence against the human cone finding.
      This is why the corresponding human node is scoped to cones.
    readouts:
    - name: Rod photoresponse amplitude and kinetics
      target: Impaired Cone Light-Response Generation and Delayed Recovery
      description: >-
        Single-cell rod photoresponses recorded from Y99C transgenic retinas.
      direction: UNCHANGED
      interpretation: >-
        Dynamic Ca2+-dependent regulation of cGMP synthesis was preserved in
        rods despite the raised dark calcium.
      evidence:
      - reference: PMID:15240799
        reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Surprisingly, there was little change in the rod photoresponse, indicating that dynamic Ca2+-dependent regulation of cGMP synthesis was preserved."
        explanation: >-
          Reports the negative photoresponse result behind this readout.
    evidence:
    - reference: PMID:15240799
      reference_title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Surprisingly, there was little change in the rod photoresponse, indicating that dynamic Ca2+-dependent regulation of cGMP synthesis was preserved."
      explanation: >-
        The authors report the preserved rod photoresponse as a surprising
        negative finding, which is the substance of this failure-to-recapitulate
        claim.
- name: GCAP1 RNAi knockdown rescue models
  species: Mouse
  genotype: Transgenic bovine GCAP1(Y99C) and mouse GCAP1(L151F), treated with scAAV2/8 shRNA against GCAP1
  publication: PMID:24778606
  description: >-
    Two dominant GCAP1 retinal degeneration mouse lines used as a therapeutic
    test bed: an allele-specific Y99C line with a rapid phenotype and a
    non-allele-specific L151F line with a slow cone-rod dystrophy that the
    authors present as the closer match to human GCAP1 disease. Subretinal
    scAAV2/8 delivering GCAP1 shRNA was used to knock the transgene down.
  evidence:
  - reference: PMID:24778606
    reference_title: "RNA interference gene therapy in dominant retinitis pigmentosa and cone-rod dystrophy mouse models caused by GCAP1 mutations."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The late onset GCAP1(L151F)-CORD mimics the dystrophy observed in human GCAP1-CORD patients."
    explanation: >-
      The authors state which of the two lines they regard as matching human
      GCAP1 cone-rod dystrophy, which is the basis for treating these models
      as informative for this disease.
  modeled_mechanisms:
  - target: Cone Photoreceptor Degeneration
    relationship: RESCUES
    fidelity: MODERATE
    description: >-
      Knocking down mutant GCAP1 enhanced photoreceptor survival, delayed
      degeneration onset, and improved visual function in both lines, which is
      the interventional counterpart of the claim that GCAP1 gain of function
      drives the degeneration.
    limitations: >-
      Both lines are transgenic overexpressors rather than knock-ins, one
      expresses a bovine transgene, and the rescue is preclinical with no
      human trial. Photoreceptor survival in a rod-dominant mouse retina is
      not a direct measure of the cone survival that matters clinically.
    readouts:
    - name: Photoreceptor survival after GCAP1 knockdown
      target: Cone Photoreceptor Degeneration
      description: >-
        Photoreceptor survival, degeneration onset, and visual function after
        subretinal scAAV2/8 shRNA delivery, compared with untreated eyes.
      direction: RESTORED
      interpretation: >-
        Removing the mutant gene product slows the degeneration, supporting
        the causal direction of this node.
      evidence:
      - reference: PMID:24778606
        reference_title: "RNA interference gene therapy in dominant retinitis pigmentosa and cone-rod dystrophy mouse models caused by GCAP1 mutations."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "RNAi-mediated gene silencing enhanced photoreceptor survival, delayed onset of degeneration and improved visual function"
        explanation: >-
          Reports the survival and function measurements behind this readout.
    evidence:
    - reference: PMID:24778606
      reference_title: "RNA interference gene therapy in dominant retinitis pigmentosa and cone-rod dystrophy mouse models caused by GCAP1 mutations."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The allele-specific model expresses transgenic bovine GCAP1(Y99C) establishing a rapid RP-like phenotype, whereas the nonallele-specific model expresses mouse GCAP1(L151F) producing a slowly progressing cone-rod dystrophy (CORD)."
      explanation: >-
        Describes what the two models are and which one the authors regard as
        matching the human cone-rod dystrophy, which is what makes them
        informative for this node.

- name: GUCA1A p.Arg120Leu zebrafish overexpression model
  species: Zebrafish
  genotype: Transient overexpression of human GUCA1A mRNA carrying p.Arg120Leu
  publication: PMID:28125083
  description: >-
    Zebrafish embryos injected with mutant human GUCA1A mRNA, with wild-type
    mRNA injected alone and co-injected as controls. Used to separate a toxic
    gain-of-function mechanism from a dominant-negative one.
  evidence:
  - reference: PMID:28125083
    reference_title: "GUCA1A mutation causes maculopathy in a five-generation family with a wide spectrum of severity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "To test the hypothesis that p.R120L causes disease through a gain-of-function mechanism, we overexpressed WT (hereafter termed GUCA1AWT) or mutated human GUCA1A mRNA (GUCA1Ap.R120L) in zebrafish to characterize their relevant pathology."
    explanation: >-
      States the design of the model and the question it was built to answer.
  modeled_mechanisms:
  - target: Cone Photoreceptor Degeneration
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Mutant-injected larvae lost cone inner-segment and outer-segment
      staining and cone cell-body signal, and co-injected wild-type mRNA did
      not rescue the loss, which is the behavior expected of a toxic
      gain-of-function allele rather than a haploinsufficiency.
    limitations: >-
      This is transient mRNA overexpression in a larval fish, not expression
      of a heterozygous allele from the endogenous locus, so the dosage is not
      physiological and the timescale is developmental rather than the adult
      degeneration seen in patients. Rod markers were lost as well as cone
      markers, which does not match the cone-predominant human phenotype.
      p.Arg120Leu is not among the alleles in the largest human cohort.
    readouts:
    - name: Cone inner segment and outer segment staining
      target: Cone Photoreceptor Degeneration
      description: >-
        Peanut agglutinin lectin staining of cone inner and outer segments in
        retinal sections at 4 days postfertilization.
      direction: DECREASED
      interpretation: >-
        Loss of cone segment structure in mutant-injected larvae.
      evidence:
      - reference: PMID:28125083
        reference_title: "GUCA1A mutation causes maculopathy in a five-generation family with a wide spectrum of severity."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "the cone inner segment/OS, indicated by peanut agglutinin lectin staining, were significantly reduced or even vanished in larvae injected with GUCA1Ap.R120L"
        explanation: >-
          Reports the cone staining measurement behind this readout.
    evidence:
    - reference: PMID:28125083
      reference_title: "GUCA1A mutation causes maculopathy in a five-generation family with a wide spectrum of severity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Thus, our findings revealed that photoreceptors are impaired by GUCA1A p.R120L in a toxic gain-of-function way."
      explanation: >-
        The authors' own conclusion that the allele acts by toxic gain of
        function, which is what makes this model informative for a
        gain-of-function degeneration node.
  notes: >-
    The same study reached the opposite conclusion for a different allele: in
    the identical assay p.Asp100Glu was rescued by co-injected wild-type
    mRNA, which the authors read as dominant-negative rather than toxic gain
    of function. Not every pathogenic GUCA1A allele is assumed here to act by
    the constitutive-activation mechanism the pathograph models, and
    p.Asp100Glu is deliberately not listed among the variants in the genetic
    section.

treatments:
- name: Supportive care and low vision rehabilitation
  therapeutic_modality: OTHER
  description: >-
    No approved disease-modifying treatment exists for GUCA1A-related
    retinopathy. Standard of care encompasses low vision aids, tinted
    lenses or filters for photophobia, orientation and mobility support as
    needed, and regular monitoring of visual function and retinal structure
    to track progression.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care

- name: Genetic counseling
  therapeutic_modality: OTHER
  description: >-
    Genetic counseling clarifies the 50% recurrence risk to offspring of an
    affected individual under autosomal dominant inheritance, supports
    cascade testing of at-risk relatives, and informs family planning and
    eligibility for future clinical trials as they become available.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling

references:
- reference: PMID:39969478
  title: "Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy."
- reference: PMID:9425234
  title: "A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1."
- reference: PMID:9651312
  title: "Constitutive activation of photoreceptor guanylate cyclase by Y99C mutant of GCAP-1. Possible role in causing human autosomal dominant cone degeneration."
- reference: PMID:28025326
  title: "Dysfunction of cGMP signalling in photoreceptors by a macular dystrophy-related mutation in the calcium sensor GCAP1."
- reference: PMID:34639157
  title: "A Novel GUCA1A Variant Associated with Cone Dystrophy Alters cGMP Signaling in Photoreceptors by Strongly Interacting with and Hyperactivating Retinal Guanylate Cyclase."
- reference: PMID:33919796
  title: "Impaired Ca(2+) Sensitivity of a Novel GCAP1 Variant Causes Cone Dystrophy and Leads to Abnormal Synaptic Transmission Between Photoreceptors and Bipolar Cells."
- reference: PMID:30679166
  title: "Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy."
- reference: PMID:15240799
  title: "The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice."
- reference: PMID:24778606
  title: "RNA interference gene therapy in dominant retinitis pigmentosa and cone-rod dystrophy mouse models caused by GCAP1 mutations."
- reference: PMID:15953638
  title: "Mutation in the gene GUCA1A, encoding guanylate cyclase-activating protein 1, causes cone, cone-rod, and macular dystrophy."
- reference: PMID:28125083
  title: "GUCA1A mutation causes maculopathy in a five-generation family with a wide spectrum of severity."

📚

References & Deep Research

References

11

PMID:39969478

Clinical, Genetic, Imaging and Electrophysiological Findings in a Cohort of Patients With GUCA1A-Associated Retinopathy.

No top-level findings curated for this source.

PMID:9425234

A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1.

No top-level findings curated for this source.

PMID:9651312

Constitutive activation of photoreceptor guanylate cyclase by Y99C mutant of GCAP-1. Possible role in causing human autosomal dominant cone degeneration.

No top-level findings curated for this source.

PMID:28025326

Dysfunction of cGMP signalling in photoreceptors by a macular dystrophy-related mutation in the calcium sensor GCAP1.

No top-level findings curated for this source.

PMID:34639157

A Novel GUCA1A Variant Associated with Cone Dystrophy Alters cGMP Signaling in Photoreceptors by Strongly Interacting with and Hyperactivating Retinal Guanylate Cyclase.

No top-level findings curated for this source.

PMID:33919796

Impaired Ca(2+) Sensitivity of a Novel GCAP1 Variant Causes Cone Dystrophy and Leads to Abnormal Synaptic Transmission Between Photoreceptors and Bipolar Cells.

No top-level findings curated for this source.

PMID:30679166

Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy.

No top-level findings curated for this source.

PMID:15240799

The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice.

No top-level findings curated for this source.

PMID:24778606

RNA interference gene therapy in dominant retinitis pigmentosa and cone-rod dystrophy mouse models caused by GCAP1 mutations.

No top-level findings curated for this source.

PMID:15953638

Mutation in the gene GUCA1A, encoding guanylate cyclase-activating protein 1, causes cone, cone-rod, and macular dystrophy.

No top-level findings curated for this source.

PMID:28125083

GUCA1A mutation causes maculopathy in a five-generation family with a wide spectrum of severity.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Address PR 9474 review: deep research, frequency fixes, module conformance, connected pathograph · 2026-09-17T17:14:07Z · View source

Follow-up on PR 9474 review (ai4c-reviewer, CHANGES_REQUESTED 2026-08-25). Deep research. Ran just research-disorder falcon GUCA1A-Related_Retinopathy with EDISON_API_KEY; the report is committed at research/GUCA1A-Related_Retinopathy-deep-research-falcon.md (769s, 39 citations). Its own reference validation resolved 10 of 10 identifiers with 0 unresolved and 0 off-topic; the single term-validation mismatch is the template string "if available" echoed beside MONDO:0700376, not a term error. just preflight-dr against MONDO:0700376 returned PASS (GUCA1A mentioned 53 times, top gene by a wide margin). Two papers the report surfaced were fetched, verified and consumed: PMID:15953638 (Michaelides 2005, one p.Tyr99Cys allele producing cone, cone-rod and isolated macular dystrophy within one family) and PMID:28125083 (Chen 2017, zebrafish p.Arg120Leu overexpression). Frequency corrections. Macular atrophy OCCASIONAL to VERY_FREQUENT on "Maculopathy was evident in all individuals on OCT imaging" (19/19); the description previously conflated the macular-dystrophy ERG pattern (2/13) with structural maculopathy, and that ERG figure now sits on the electroretinogram phenotype instead. Color vision defect FREQUENT to VERY_FREQUENT on the 84.2 percent figure. Photophobia stays FREQUENT but is now sourced on the GUCA1A-specific 78.9 percent rather than the class-level review, which is retained as a second item marked OTHER. Pathograph. The bundled node "Cone Photoreceptor Calcium Overload and Degeneration" was split into four atomic nodes: sustained CNG channel opening and outer-segment calcium overload (conforms_to phototransduction_cascade_dysfunction hash cGMP and Calcium Overload Handoff to Photoreceptor Degeneration), impaired cone light-response generation and delayed recovery (conforms_to the module key target, Failure of Photoreceptor Light-Response Generation or Timely Recovery), abnormal photoreceptor-to-ON-bipolar synaptic transmission, and cone photoreceptor degeneration. A fifth node, variable rod photoreceptor involvement, carries the peripheral pigmentary and nyctalopia phenotypes. Downstream edges now reach the phenotype layer; the graph has no integrity issues, no orphan targets, and no disconnected node other than the two non-mechanistic treatments. Conformance declined and why. The module node instructs a conforming disorder to also declare photoreceptor_degeneration conformance. That module is rod-first and models cone loss as non-cell-autonomous after rod elimination, whereas GUCA1A disease is cone-first because GCAP1 expression is higher in cones. Declaring conformance there would assert a sequence this disease does not follow. The reasoning is recorded in notes on the calcium-overload node. Cone-scoped light-response node. The Y99C transgenic mouse showed little change in the rod photoresponse despite raised dark outer-segment Ca2+, and human dark-adapted ERGs were normal in all but one tested patient. The node is therefore scoped to cones and the mouse link is recorded as FAILS_TO_RECAPITULATE with limitations and evidence. Added sections. prevalence (US extrapolation 1 in 247,143, recorded as 0.4 per 100,000 in BAND_1_9_PER_1000000, not the reviewer-suggested BELOW_1_IN_1000000, which the arithmetic does not support; plus an unbanded IRD-cohort-share record), progression (three phases: onset, 0.20 logMAR per decade acuity decline, structural macular staging), diagnosis (molecular testing, multimodal imaging, electrophysiology), animal_models (Y99C transgenic mouse with three mechanism links, GCAP1 RNAi rescue models, R120L zebrafish), onset descriptor on Progressive visual loss, a MALE phenotype_context on Reduced visual acuity, and three new phenotypes (central scotoma, peripheral pigmentary retinopathy, nyctalopia). Nyctalopia is banded OCCASIONAL, not the VERY_RARE first drafted: 5.3 percent falls inside the 5-29 percent band. GAIN_OF_FUNCTION now also sits on GeneticContext.functional_impact_category on the trigger node, with allele_type, variant_origin and zygosity, alongside the existing descriptor modifier. Validation. just validate passes: schema, terms, and reference validation clean, 57/57 snippets verified against cached references. Full tests/test_data.py: 6726 passed. check-duplicate-keys, check-title-snippets, check-entity-refs, check-folded-hyphens, check-empty-snippets, check-causal-targets and check-enum-values all clean. Every reference title was rewritten programmatically from the cache frontmatter rather than typed.

Falcon ▸

GUCA1A-Related Retinopathy: Disease Characteristics Research Report

Edison Scientific Literature 39 citations 2026-09-17T12:54:18.609345

GUCA1A-Related Retinopathy: Disease Characteristics Research Report

Executive summary

GUCA1A-related retinopathy (MONDO:0700376) is a rare, nonsyndromic, usually autosomal-dominant inherited retinal disease caused by heterozygous missense variants in GUCA1A, which encodes guanylate cyclase-activating protein 1 (GCAP1). It forms a phenotypic continuum encompassing macular dystrophy, cone dystrophy, cone–rod dystrophy and, rarely, an RP-like generalized degeneration. The core manifestations are progressive, bilateral central visual loss, impaired color discrimination and photophobia, with outer-retinal/macular atrophy and cone-predominant electroretinographic dysfunction. The best quantitative disease-specific natural-history evidence is a 2025 retrospective cohort of 19 patients from 14 families; no comparably comprehensive 2023–2024 clinical cohort was retrieved. (OpenTargets Search: GUCA1A-related retinopathy-GUCA1A, allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 4-5)

The principal mechanism is not simple haploinsufficiency. Most pathogenic GCAP1 variants impair Ca²⁺ sensing and permit inappropriate activation of retinal guanylate cyclase at Ca²⁺ concentrations that should inhibit it, disturbing cGMP/Ca²⁺ homeostasis and ultimately injuring photoreceptors. There is currently no approved GUCA1A-specific disease-modifying treatment or relevant human interventional trial in the retrieved evidence. AAV-delivered RNA interference has delayed degeneration and improved function in mutant-GCAP1 mice, but remains preclinical. (marino2018anovelp.(glu111val) pages 3-3, kitiratschky2009mutationsinthe pages 1-3, dell’orco2019normalgcapspartly pages 1-2, jiang2013rnaimediatedgenesuppression pages 13-13)

The following compact table is suitable for initial knowledge-base ingestion.

Knowledge-base field	Evidence-based summary	Suggested ontology mapping	Evidence
Disease identity	Rare inherited retinal dystrophy spanning macular dystrophy, cone dystrophy, cone–rod dystrophy and, less often, an RP-like phenotype; designated GUCA1A-related retinopathy.	MONDO:0700376	(OpenTargets Search: GUCA1A-related retinopathy-GUCA1A, allon2025clinicalgeneticimaging pages 1-2)
Gene/protein	GUCA1A encodes guanylate cyclase-activating protein 1 (GCAP1), a neuronal calcium sensor expressed in rod and cone photoreceptors and involved in recovery of phototransduction.	Suggested gene/protein annotations: GUCA1A, GCAP1	(kitiratschky2009mutationsinthe pages 1-3, marino2018anovelp.(glu111val) pages 1-1)
Inheritance	Predominantly autosomal dominant, caused by heterozygous germline missense variants; multigenerational disease was present in 13 of 14 families in the largest reported cohort. Penetrance is not reliably quantified, and expressivity is highly variable.	Suggested HPO: Autosomal dominant inheritance	(allon2025clinicalgeneticimaging pages 4-5, marino2018anovelp.(glu111val) pages 8-9, kitiratschky2009mutationsinthe pages 1-3)
Core phenotypes	Progressive bilateral central visual loss, impaired color discrimination and photophobia; central/paracentral scotomas, macular/outer-retinal atrophy and reduced cone ERG responses are typical. Rod dysfunction is usually absent or later/milder, but severe cone–rod disease occurs.	Suggested HPO: Progressive visual loss, Reduced visual acuity, Abnormal color vision, Photophobia, Central scotoma, Macular atrophy, Cone dystrophy, Cone-rod dystrophy, Abnormal electroretinogram, Nystagmus	(allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 5-10, marino2018anovelp.(glu111val) pages 2-3)
Mechanism	Missense variants—often affecting GCAP1 EF-hand calcium-sensing regions—reduce calcium sensitivity and permit persistent retinal guanylate-cyclase activation at calcium concentrations that should inhibit it. This dysregulates cGMP and Ca²⁺ homeostasis and leads to photoreceptor dysfunction and degeneration; the final cell-death pathway is supported strongly by models but is not fully resolved in humans.	Suggested GO biological processes: visual phototransduction, phototransduction recovery, calcium ion sensing, regulation of guanylate cyclase activity, cGMP biosynthetic process, calcium ion homeostasis, photoreceptor cell death	(marino2018anovelp.(glu111val) pages 3-3, kitiratschky2009mutationsinthe pages 1-3, dell’orco2019normalgcapspartly pages 1-2, payne1998amutationin pages 3-3)
Cells/anatomy	Primary targets are macular cone photoreceptors and, variably, rod photoreceptors; abnormalities begin in the outer photoreceptor/ellipsoid-zone region. RPE involvement occurs with advanced human maculopathy and in zebrafish models. Disease is generally bilateral and highly symmetric.	Suggested CL: cone photoreceptor cell, rod photoreceptor cell, retinal pigment epithelial cell. Suggested UBERON: retina, macula, neural retina, photoreceptor outer segment, retinal pigment epithelium	(allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 13-13, chen2017guca1amutationcauses pages 7-8)
Diagnostics	Clinical assessment should combine visual acuity and color-vision evaluation with fundus examination, fundus autofluorescence, macular SD-OCT, visual fields and ISCEV-standard pattern/full-field ERG. Molecular confirmation can use an inherited-retinal-disease panel, WES or WGS, followed by Sanger/segregation testing and ACMG/AMP interpretation.	Suggested HPO-linked findings: Ellipsoid-zone disruption, Outer retinal atrophy, Central scotoma, Reduced cone ERG response	(allon2025clinicalgeneticimaging pages 4-5, marino2018anovelp.(glu111val) pages 2-3, allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 2-4)
Prognosis	Chronic, generally progressive and nonlethal. In 19 patients, mean onset was 23 years (range 5–74), and visual acuity worsened by approximately 0.20 logMAR per decade, although severity ranged from preserved acuity beyond age 70 to no light perception. Possible variant-specific and sex effects require confirmation.	Suggested HPO: Variable age at onset, Progressive visual impairment, Variable expressivity	(allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 10-10)
Treatment status	No GUCA1A-specific approved disease-modifying therapy or relevant registered interventional trial was identified in the gathered evidence. Present care is supportive and rehabilitative. AAV8-delivered RNA interference delayed degeneration and improved function in mutant-GCAP1 mice, but remains preclinical and carries normal-allele suppression/off-target concerns.	Suggested NCIT intervention concepts: Low Vision Rehabilitation, Genetic Counseling, Gene Silencing Therapy, Adeno-Associated Virus Vector Therapy	(jiang2013rnaimediatedgenesuppression pages 13-13, jiang2013rnaimediatedgenesuppression pages 1-2, jiang2012rnainterferencegene pages 158-159)
Experimental models	Engineered mouse models include transgenic Y99C, transgenic L151F and knock-in E155G, which reproduce dominant, progressive photoreceptor dysfunction with cone-predominant degeneration. Zebrafish overexpressing human R120L show photoreceptor and RPE disruption. These are induced genetic models, not documented natural veterinary disease.	Suggested model annotations: Mus musculus genetic disease model; Danio rerio overexpression model	(jiang2013rnaimediatedgenesuppression pages 13-13, dell’orco2019normalgcapspartly pages 1-2, chen2017guca1amutationcauses pages 7-8)
Evidence gaps	Disease-specific incidence, population prevalence, penetrance, carrier frequency, founder effects, validated modifier genes, environmental or protective factors, gene–environment interactions, epigenetic signatures, human single-cell/spatial multi-omics, standardized quality-of-life data, natural animal disease and human treatment-response rates are not established in the gathered evidence.	No ontology assignment recommended until evidence is available.	(allon2025clinicalgeneticimaging pages 2-4, avesani2026retinalnetworkdysfunction pages 12-14, allon2025clinicalgeneticimaging pages 1-2)

Table: Compact evidence table covering disease identity, genetics, phenotype, mechanism, diagnostic approach, prognosis, treatment status, experimental models and major knowledge gaps. Ontology mappings are explicitly suggested rather than asserted.

1. Disease information

Definition and scope

GUCA1A-related retinopathy is a Mendelian photoreceptor degeneration in which cone dysfunction usually dominates. Clinical labels historically assigned to affected families include:

GUCA1A-associated/related retinopathy or retinal dystrophy;
GCAP1-related retinopathy;
autosomal-dominant cone dystrophy, historically cone dystrophy 3/COD3;
autosomal-dominant cone–rod dystrophy;
GUCA1A-related macular dystrophy or maculopathy;
central areolar choroidal dystrophy-like maculopathy;
rarely, an RP-like phenotype. (allon2025clinicalgeneticimaging pages 1-2, chen2017guca1amutationcauses pages 7-8, georgiou2020retinalimagingin pages 13-15)

The foundational 1998 report identified p.Tyr99Cys in an autosomal-dominant cone-dystrophy pedigree. A later clinical series established that GUCA1A variants can cause “cone, cone-rod, and macular dystrophy” (Michaelides et al., Ophthalmology, August 2005; PMID 15953638). (payne1998amutationin pages 3-3, georgiou2020retinalimagingin pages 13-15)

Identifiers

MONDO: MONDO:0700376, GUCA1A-related retinopathy; Open Targets maps this entity principally to GUCA1A/ENSG00000048545. (OpenTargets Search: GUCA1A-related retinopathy-GUCA1A)
Gene: GUCA1A; approved name guanylate cyclase activator 1A.
A disease-specific ICD-10, ICD-11 or MeSH code was not established in the retrieved sources; implementation should use a broader inherited retinal/cone–rod dystrophy code plus the molecular diagnosis.
OMIM/Orphanet identifiers should be verified directly against those live resources before database ingestion; the retrieved primary texts did not provide a sufficiently reliable disease-level identifier.

This report synthesizes aggregated disease-level literature and retrospective cohorts, not individual EHR records. The 2025 study used molecularly confirmed clinical records from a specialist referral center. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 1-2)

2. Etiology, risk and protective factors

Causal factor

The primary cause is a heterozygous germline GUCA1A missense variant, generally producing altered-function GCAP1. Familial segregation and multigenerational transmission support autosomal-dominant causality. All 19 patients in the largest cohort carried pathogenic or likely pathogenic heterozygous missense alleles. (allon2025clinicalgeneticimaging pages 5-10, marino2018anovelp.(glu111val) pages 8-9, kitiratschky2009mutationsinthe pages 1-3)

Genetic risk factors

Disease risk is dominated by carrying a pathogenic allele. Variants frequently affect or perturb the EF-hand Ca²⁺-sensing regions. Documented alleles include p.Tyr99Cys, p.Asp100Glu, p.Asn104His, p.Ile107Thr, p.Glu111Ala/Val, p.Arg120Leu, p.Leu151Phe, p.Glu155Gly, p.Gly159Val, p.Leu176Phe, p.Leu84Phe and p.Glu89Lys. The 2025 cohort contained five alleles: p.Tyr99Cys in 10 of 14 families, with p.Leu84Phe, p.Ile107Thr, p.Glu111Ala and p.Leu176Phe in one family each. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 2-4, marino2018anovelp.(glu111val) pages 3-3, kitiratschky2009mutationsinthe pages 1-3, chen2017guca1amutationcauses pages 7-8)

Family history is therefore a major risk indicator, but apparently sporadic cases may represent de novo variants or unrecognized reduced penetrance. Penetrance is not robustly quantified. Marked inter- and intrafamilial variability is documented; p.Arg120Leu produced maculopathy ranging from mild photoreceptor degeneration to severe central areolar choroidal dystrophy in one five-generation family. (allon2025clinicalgeneticimaging pages 10-10, chen2017guca1amutationcauses pages 7-8, georgiou2020retinalimagingin pages 13-15)

Modifiers and protective factors

No validated human modifier gene or protective allele has been established. Wild-type GCAP1 partly attenuated E111V-induced cyclase dysregulation in biochemical experiments. Mouse modeling suggested GCAP2 may add compensation, but human GCAP2 did not activate GC1 over the tested physiological Ca²⁺ range; this is a proposed species-dependent compensatory mechanism, not a proven human modifier. (dell’orco2019normalgcapspartly pages 1-2)

No disease-specific protective diet, lifestyle intervention or medication is established. Environmental toxins, smoking, alcohol, occupation, infection, sex and age are not primary causes. A 2025 cohort found worse acuity in males, but this exploratory association requires replication. Age predicts accumulated severity rather than genetic susceptibility. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 10-10)

Gene–environment interaction

No reproducible GUCA1A-specific gene–environment interaction was found. Ordinary light drives the pathway in which GCAP1 functions, but available evidence does not establish routine light exposure as a modifiable cause or prove that light avoidance changes progression.

3. Phenotypes

In the 2025 cohort, mean symptom onset was 23 years (range 5–74). Initial complaints were impaired color discrimination in 68.4%, central visual loss in 21.1%, photophobia in 5.3% and unremembered in 5.3%. Across follow-up, central visual deficits occurred in 89.5%, color deficits in 84.2% and photophobia in 78.9%; nyctalopia and metamorphopsia each occurred in 5.3%. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 10-10)

Phenotype	Type and characteristics	Suggested HPO term
Reduced central visual acuity	Symptom/sign; bilateral, usually progressive; severity ranges from mild loss to no light perception	Reduced visual acuity; Progressive visual loss
Abnormal color vision	Symptom; often the earliest complaint and common during follow-up	Abnormality of color vision
Photophobia	Symptom; common once cone dysfunction is established	Photophobia
Central/paracentral scotoma	Functional sign; reported on available visual fields	Central scotoma; Paracentral scotoma
Cone dystrophy	Electrophysiologic/clinical phenotype; 11/13 tested patients in the 2025 cohort	Cone dystrophy; Abnormal cone ERG
Cone–rod dystrophy	More severe branch with later or concurrent rod involvement	Cone-rod dystrophy; Abnormal rod ERG
Macular dystrophy/atrophy	Structural sign; OCT maculopathy in all 19 recent patients	Macular dystrophy; Macular atrophy
Ellipsoid-zone/outer-retinal loss	Imaging sign; begins as irregularity or optical gap and progresses to outer-nuclear-layer/RPE atrophy	Abnormal retinal morphology; Retinal atrophy
Nystagmus	Usually severe congenital/early-onset disease, including E111V	Nystagmus
Nyctalopia	Uncommon in cone-predominant disease; may occur with generalized rod involvement	Nyctalopia
Peripheral pigmentary degeneration	Uncommon; described with some p.Tyr99Cys and p.Glu111Ala cases	Retinal pigmentary degeneration

These mappings are suggested labels; exact HPO identifiers should be resolved through the current HPO release. The phenotype is generally highly symmetric between eyes. Rod-specific ERGs are often normal, while severe E111V disease can reduce both cone and rod responses. (allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 5-10, marino2018anovelp.(glu111val) pages 2-3)

No GUCA1A-specific EQ-5D, SF-36, PROMIS or validated vision-related quality-of-life dataset was found. Nevertheless, progressive loss of central acuity, color discrimination and light tolerance predict substantial effects on reading, facial recognition, driving, education and employment; these functional consequences are clinical inference rather than quantified disease-specific outcomes.

4. Genetic and molecular information

Gene and variant classes

GUCA1A encodes GCAP1, a neuronal calcium-sensor expressed in rods and cones, with stronger cone immunoreactivity. The disease-associated variants in the retrieved human series were overwhelmingly germline, heterozygous missense variants. No recurrent pathogenic copy-number alteration, aneuploidy, translocation, repeat expansion, mitochondrial mutation or somatic mechanism was established. (kitiratschky2009mutationsinthe pages 1-3, payne1998amutationin pages 3-3)

Representative HGVS alleles include:

NM_000409:c.332A>T, p.Glu111Val—absent from public databases available to its discoverers; failed to inhibit cyclase adequately at high Ca²⁺. (marino2018anovelp.(glu111val) pages 3-3)
c.265G>A, p.Glu89Lys; c.300T>A, p.Asp100Glu; c.476G>T, p.Gly159Val; and c.451C>T, p.Leu151Phe—all altered Ca²⁺-dependent cyclase regulation. The novel alleles were absent from 200 control chromosomes, but precise modern gnomAD frequencies were not supplied. (kitiratschky2009mutationsinthe pages 1-3)
c.250C>T, p.Leu84Phe and c.320T>C, p.Ile107Thr—reported in autosomal-dominant retinal degeneration; functional mechanism was initially predicted rather than fully demonstrated. (allon2025clinicalgeneticimaging pages 2-4)
p.Asn104His doubled the reported inhibitory midpoint from 260 nM for wild type to 520 nM and increased GC affinity, consistent with persistent activity at physiological Ca²⁺. This biochemical result was reported in 2021, not in a 2023–2024 human trial.

Variant classification must be performed allele by allele under current ACMG/AMP criteria. A missense change or rare population frequency alone is insufficient; segregation, phenotype match, functional data and independent observations are important. The 2025 cohort used ACMG classification and included only pathogenic/likely pathogenic alleles. (allon2025clinicalgeneticimaging pages 5-10, allon2025clinicalgeneticimaging pages 4-5)

Modifiers, epigenetics and structural variation

No validated modifier gene, disease-specific methylation signature, histone alteration or chromatin mechanism was identified. Likewise, no recurrent large chromosomal abnormality defines this disorder.

5. Environmental information

This is primarily a genetic photoreceptor disorder. No causal toxin, radiation exposure, pollutant, occupation, diet, smoking pattern, alcohol exposure or infectious agent is established. There is no zoonotic or transmissible component. Evidence is insufficient to claim that sunglasses, supplements or dietary manipulation alter the molecular course, although glare control may improve comfort symptomatically.

6. Mechanism and pathophysiology

Ordered causal chain

A heterozygous GUCA1A missense lesion leads to structurally altered GCAP1, commonly affecting Ca²⁺ coordination or conformational switching in EF-hand regions. (marino2018anovelp.(glu111val) pages 8-9, payne1998amutationin pages 3-3)
Altered GCAP1 leads to reduced Ca²⁺ sensitivity or stabilization of the Mg²⁺-bound activating conformation. (marino2018anovelp.(glu111val) pages 8-9, marino2018anovelp.(glu111val) pages 3-3)
This leads to failure to suppress retinal guanylate cyclase—principally GC1/RetGC1 encoded by GUCY2D—when intracellular Ca²⁺ is high, including dark-adapted conditions. (marino2018anovelp.(glu111val) pages 3-3, dell’orco2019normalgcapspartly pages 1-2)
Persistent cyclase activity leads to excessive or mistimed cGMP synthesis and impaired recovery/homeostasis of phototransduction. (kitiratschky2009mutationsinthe pages 1-3, dell’orco2019normalgcapspartly pages 1-2)
Excess cGMP leads to persistent opening/dysregulation of cGMP-gated channels and increased outer-segment Ca²⁺ load; the exact quantitative chain is demonstrated most strongly in biochemical and animal systems and inferred in human retina. (dell’orco2019normalgcapspartly pages 1-2)
Branch A: disturbed cGMP/Ca²⁺ homeostasis leads to early cone/rod response abnormalities and synaptic/network dysfunction. Branch B: chronic second-messenger toxicity leads to photoreceptor stress and death; downstream death effectors are not fully resolved for human GUCA1A disease. (jiang2013rnaimediatedgenesuppression pages 13-13, avesani2026retinalnetworkdysfunction pages 14-17, avesani2026retinalnetworkdysfunction pages 12-14)
Cone-predominant photoreceptor dysfunction and loss lead to color-vision impairment, photophobia, central scotoma and reduced central acuity; broader rod involvement leads to cone–rod or RP-like disease. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 5-10, marino2018anovelp.(glu111val) pages 2-3)
Progressive outer-retinal and later RPE atrophy results in chronic, irreversible macular degeneration and severe visual disability. (allon2025clinicalgeneticimaging pages 10-13, chen2017guca1amutationcauses pages 7-8)

Normal pathway and protein dysfunction

In light, phototransduction lowers cytoplasmic cGMP, closes cyclic-nucleotide-gated channels, hyperpolarizes the photoreceptor and lowers intracellular Ca²⁺. Low-Ca²⁺/Mg²⁺-bound GCAP1 activates RetGC to replenish cGMP; at high dark-state Ca²⁺, Ca²⁺-bound GCAP1 suppresses cyclase. Disease variants uncouple this feedback. (kitiratschky2009mutationsinthe pages 1-3, payne1998amutationin pages 3-3)

The 2018 E111V study found no major secondary/tertiary structural rearrangement but did find stabilization/rigidification of the activating state and residual cyclase activation at high Ca²⁺. Its key conclusion, reflected directly in the title, was that the variant “leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors.” (marino2018anovelp.(glu111val) pages 8-9, marino2018anovelp.(glu111val) pages 3-3)

Cells, processes and ontology suggestions

Cell types: cone photoreceptor cell; rod photoreceptor cell; retinal pigment epithelial cell. Suggested CL concepts should be matched to the current Cell Ontology.
GO biological processes: visual phototransduction; phototransduction recovery; detection of light stimulus; calcium-ion sensing; regulation of guanylate cyclase activity; cGMP biosynthetic process; calcium-ion homeostasis; photoreceptor-cell maintenance; photoreceptor-cell death.
GO cellular components: photoreceptor outer segment; photoreceptor inner segment; plasma membrane; cytosol.

Inflammation is not established as an initiating human mechanism. Early mitochondrial, synaptic and inflammatory alterations were reported only in a 2026 E111V mouse preprint and should be treated as emerging model evidence, not settled human pathophysiology. (avesani2026retinalnetworkdysfunction pages 14-17)

Molecular profiling and advanced technologies

No disease-specific human single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic or epigenomic signature was identified. Biophysical assays, molecular-dynamics simulations and engineered animal studies currently provide more mechanistic resolution than human omics. (marino2018anovelp.(glu111val) pages 8-9, marino2018anovelp.(glu111val) pages 3-3)

7. Anatomical structures affected

Organ/system: eye; retina within the visual nervous system. No consistent extraocular syndrome is established.
Primary site: bilateral neural retina, especially central macula and cone-rich outer retina.
Cells: cone photoreceptors first or most severely; rods variably; RPE becomes involved in advanced maculopathy and in zebrafish models.
Subcellular site: GCAP1-mediated signaling at photoreceptor outer-segment membranes in association with retinal guanylate cyclase; OCT abnormalities localize initially to the ellipsoid/outer-photoreceptor zone.
Suggested UBERON concepts: eye, retina, neural retina, macula, retinal pigment epithelium, photoreceptor outer segment.
Lateralization: bilateral, generally highly symmetric; the 2025 interocular acuity correlation was 0.90. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 10-13, chen2017guca1amutationcauses pages 7-8)

8. Temporal development

Onset is chronic and usually insidious, ranging from childhood to late adulthood. In the largest cohort, mean onset was 23 years and the range was 5–74. Severe E111V disease may present congenitally with nystagmus, photophobia and marked acuity loss. (allon2025clinicalgeneticimaging pages 4-5, marino2018anovelp.(glu111val) pages 2-3)

A practical staging framework is:

Early functional disease: color discrimination difficulty and photophobia; FAF may be abnormal before color fundus examination.
Early structural maculopathy: ellipsoid-zone irregularity or optical gap.
Established cone dystrophy: reduced photopic ERG, central/paracentral scotoma and progressive acuity loss.
Advanced macular/cone–rod disease: outer-retinal and outer-nuclear-layer atrophy, RPE atrophy and possible peripheral degeneration.
End-stage visual impairment: extensive photoreceptor loss and, in rare severe cases, light perception or no light perception. (allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 5-10)

Visual acuity declined by approximately 0.20 logMAR per decade in the 2025 cohort, but progression is highly variable and some individuals retain relatively good vision beyond age 70. There is no established remission pattern; the disease is chronic and generally progressive. (allon2025clinicalgeneticimaging pages 4-5, allon2025clinicalgeneticimaging pages 10-10)

9. Inheritance and population

Inheritance is predominantly autosomal dominant. Thirteen of 14 families in the largest cohort had multiple-generation involvement. Each child of a heterozygous affected individual ordinarily has a 50% transmission probability, although clinical severity cannot be predicted reliably. (allon2025clinicalgeneticimaging pages 4-5)

Penetrance is not accurately quantified. Two apparently sporadic cases could not distinguish de novo variation from reduced penetrance. Expressivity is clearly variable, including within families. No genetic anticipation, recurrent germline mosaicism, consanguinity effect or established founder allele was identified. Because affected heterozygotes are not asymptomatic “carriers” in the recessive sense, carrier-frequency language is generally inappropriate; population pathogenic-allele frequency remains unknown. (allon2025clinicalgeneticimaging pages 10-10, chen2017guca1amutationcauses pages 7-8)

Disease-specific population prevalence and incidence are unavailable. GUCA1A accounted for approximately 0.1%–0.7% of IRD cohorts, 3% of one autosomal-dominant non-RP subgroup, and 1.2% of a German macular/cone-dystrophy cohort (1.6% among molecularly solved cases). These are referral-cohort proportions, not population prevalence. (allon2025clinicalgeneticimaging pages 2-4)

No reproducible ethnic, geographic or sex ratio has been established. The recent male-severity signal should not be interpreted as male-limited inheritance. (allon2025clinicalgeneticimaging pages 4-5)

10. Diagnostics

Clinical workflow

Record onset, progression, family history, photophobia, color impairment, central vision and nyctalopia.
Measure best-corrected visual acuity and perform slit-lamp/fundus examination.
Test color discrimination and central/peripheral visual fields.
Obtain macular spectral-domain OCT, short-wavelength fundus autofluorescence and widefield color/pseudocolor imaging.
Use ISCEV-standard pattern ERG to assess macular function and full-field ERG, including photopic on–off responses, to distinguish cone-predominant from cone–rod disease.
Confirm molecularly with an inherited-retinal-disease NGS panel, WES or WGS; validate/phase and assess segregation by Sanger sequencing when appropriate; classify under current ACMG/AMP standards. (allon2025clinicalgeneticimaging pages 4-5, marino2018anovelp.(glu111val) pages 2-3, allon2025clinicalgeneticimaging pages 2-4)

FAF may detect maculopathy before conventional fundus abnormalities but is not genotype-specific. OCT typically progresses from ellipsoid-zone irregularity/optical gap to outer-retinal, outer-nuclear-layer and RPE atrophy. PERG P50 is often undetectable with severe macular involvement. Full-field ERG distinguished cone dystrophy in 11/13 tested recent patients from macular dystrophy with normal full-field responses in 2/13. (allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 5-10)

CMA, karyotyping, FISH, mtDNA analysis and repeat-expansion testing are not first-line for a classic dominant GUCA1A phenotype. They may be used only when the broader presentation suggests another diagnosis. RNA-seq and other omics are research tools, not validated diagnostics.

Differential diagnosis

The differential includes other inherited cone/cone–rod or macular dystrophies—especially GUCY2D, PRPH2, ABCA4, CRX, RPGR, PROM1, CDHR1, CNGA3/CNGB3—and acquired toxic, autoimmune or age-related maculopathy. Distinguishing clues are dominant transmission, cone-predominant ERG dysfunction, symmetric outer-retinal maculopathy and a pathogenic GUCA1A allele. Imaging alone is insufficient because FAF/OCT appearances overlap across genotypes. (allon2025clinicalgeneticimaging pages 10-13, georgiou2020retinalimagingin pages 13-15)

Screening

Population or newborn screening is not established. Cascade genetic testing is appropriate for adult relatives after the familial pathogenic variant is known. Predictive testing of minors requires genetics/ophthalmology counseling and consideration of whether results alter childhood surveillance or management.

11. Outcome and prognosis

GUCA1A retinopathy is not known to reduce life expectancy or cause disease-specific mortality. Morbidity is visual. In the 2025 cohort, mean right-eye acuity changed from 0.67 to 0.94 logMAR and left-eye acuity from 0.63 to 0.95 over a mean follow-up of approximately 10 years; the observed range extended from 0.00 logMAR to no light perception. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 4-5)

Prognostic indicators include age, baseline macular structure/function and probably genotype. p.Leu84Phe was associated with earlier loss, p.Glu111Ala with worse vision, and p.Ile107Thr with later/milder disease, but each rare subgroup was very small. Extensive central atrophy and complete photoreceptor-layer loss correlate with worse acuity. (allon2025clinicalgeneticimaging pages 10-13, allon2025clinicalgeneticimaging pages 10-10)

Recovery of lost photoreceptors is not expected with current supportive care. A rare Coats-like reaction with exudative retinal detachment was reported, but this is not a typical complication. No validated circulating or molecular prognostic biomarker exists beyond genotype and retinal structural/functional measures. (allon2025clinicalgeneticimaging pages 4-5)

12. Treatment

Current clinical care

No GUCA1A-specific pharmacotherapy, gene therapy, RNA therapy, cell therapy or approved surgical treatment was identified. Present management is supportive:

individualized refractive correction;
tinted lenses/glare control for photophobia;
low-vision assessment and optical/electronic aids;
orientation, mobility, educational and occupational accommodations;
monitoring by an inherited-retinal-disease service using acuity, OCT/FAF and functional testing;
treatment of unrelated or secondary ocular complications according to standard practice;
genetic counseling and access to IRD registries/natural-history research.

Suggested NCIT intervention concepts are Low Vision Rehabilitation, Assistive Device, Genetic Counseling, Gene Silencing Therapy, and Adeno-Associated Virus Vector Therapy; the latter two are experimental for this disease.

Preclinical advanced therapeutics

A non-allele-specific silencing strategy is mechanistically attractive because many variants are dominant gain-of-function alleles. In L151F mice, scAAV2/8-delivered shRNA suppressed mutant GCAP1 by about 70% and endogenous GCAP1 by about 90%. In a Y99C model, approximately 80% transgene silencing persisted for nearly one year and improved photoreceptor survival, delayed degeneration and improved visual function. Risks include suppression of normal GCAP1, RNAi saturation and off-target effects. (jiang2013rnaimediatedgenesuppression pages 13-13, jiang2013rnaimediatedgenesuppression pages 1-2)

The investigators characterized these results as a “proof of concept” for RNAi-based treatment of dominant GCAP1 disease. No human response rate or safety estimate exists. Gene supplementation alone is unlikely to neutralize a dominant toxic allele; silencing-and-replacement, allele-specific RNAi, antisense approaches or editing may ultimately be more appropriate. (jiang2012rnainterferencegene pages 158-159)

No relevant GUCA1A human interventional trial/NCT identifier was found. A search hit for “GCAP” referred to an unrelated bladder-cancer chemotherapy acronym and must not be included as a retinal trial.

13. Prevention

Primary lifestyle prevention is unavailable because the initiating cause is inherited. Secondary prevention consists of molecular diagnosis, surveillance and identifying relatives early enough for counseling, visual support and future trial eligibility. Tertiary prevention aims to limit disability through glare control, low-vision rehabilitation, workplace/school accommodation and treatment of secondary ocular complications.

Genetic counseling should explain autosomal-dominant transmission, variable expressivity and uncertain severity. Once a familial pathogenic variant is established, reproductive options may include prenatal diagnosis or preimplantation genetic testing, subject to local regulation and nondirective counseling. Vaccination, antimicrobial prophylaxis and public-health environmental measures are not applicable.

14. Other species and natural disease

No naturally occurring GUCA1A-equivalent veterinary disease was identified in companion animals, livestock or wildlife. There is no zoonotic potential or cross-species transmission. Orthologous Guca1a genes in mouse and zebrafish support strongly conserved calcium-dependent phototransduction, but the reported diseases are engineered experimental models rather than natural animal cases. Exact NCBI Gene and Taxon identifiers should be resolved directly from current NCBI records before ingestion.

15. Model organisms

Mouse models (Mus musculus)

Y99C transgenic: rapid, expression-dose-dependent photoreceptor degeneration and a useful allele-specific RNAi model. (dell’orco2019normalgcapspartly pages 1-2, jiang2012rnainterferencegene pages 158-159)
L151F genomic transgenic: late-onset, slowly progressive cone–rod degeneration resembling human GCAP1-CORD; photopic b-wave was approximately 60% of normal at 12 months. (jiang2013rnaimediatedgenesuppression pages 13-13, jiang2013rnaimediatedgenesuppression pages 1-2)
E155G knock-in: normal early development followed by progressive cone-predominant dysfunction and photoreceptor loss; 12-month photopic b-wave was approximately 42% of normal. cGMP accumulation preceded structural degeneration, supporting its upstream pathogenic role. (jiang2013rnaimediatedgenesuppression pages 13-13)
E111V knock-in: a 2026 non-peer-reviewed preprint reports functional/network abnormalities before major structural loss, with outer-nuclear-layer thinning only later. Acute ex-vivo wild-type GCAP1 partially corrected rod-response kinetics; this is proof of biochemical modifiability, not therapeutic efficacy. (avesani2026retinalnetworkdysfunction pages 14-17, avesani2026retinalnetworkdysfunction pages 12-14)

Mouse limitations include a rod-dominant retina, transgene dosage effects, retention of endogenous normal alleles in some lines and species-specific GCAP2 compensation. These differences can exaggerate or attenuate the human cone-predominant phenotype. (jiang2013rnaimediatedgenesuppression pages 13-13, dell’orco2019normalgcapspartly pages 1-2)

Zebrafish (Danio rerio)

Overexpression of human p.Arg120Leu reduced rod/cone markers, disrupted photoreceptors and RPE, and affected retinal/choriocapillaris-associated vasculature. Wild-type GUCA1A did not fully rescue the phenotype, supporting altered/gain-of-function behavior. p.Asp100Glu also injured photoreceptors and RPE, with a proposed dominant-negative mechanism. These are overexpression models and may not reproduce physiological heterozygous dosage. The corresponding human study was published in Genetics in Medicine in August 2017, DOI 10.1038/gim.2016.217, PMID 28125083. (chen2017guca1amutationcauses pages 7-8, georgiou2020retinalimagingin pages 13-15)

No disease-specific human iPSC, retinal-organoid, Drosophila, C. elegans, yeast or naturally affected animal model was established in the retrieved evidence.

Recent developments and evidence gaps

The most important recent advance is the 2025 largest-cohort study, which quantified onset, longitudinal acuity decline, symptom frequencies, bilateral symmetry, OCT sequence and preliminary genotype–phenotype associations. It was published February 19, 2025, DOI 10.1167/iovs.66.2.50. The strongest 2023 contribution retrieved was a review emphasizing that dominant retinal diseases often require silencing, editing or combined suppression/replacement rather than simple gene augmentation; no GUCA1A human program had entered clinical testing. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 4-5)

Major unresolved fields are population prevalence/incidence, penetrance, founder effects, validated modifiers, gene–environment interaction, standardized quality-of-life outcomes, human retinal omics, biomarkers, prospective natural history and human therapeutic trials. The 2025 cohort’s modest size—19 patients and only one family for four of five alleles—means variant-specific prognostic estimates remain preliminary. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 10-10)

Key primary references

Payne A, et al. Human Molecular Genetics. February 1998. “A mutation in guanylate cyclase activator 1A….” DOI: 10.1093/hmg/7.2.273. Foundational human Y99C pedigree. (payne1998amutationin pages 3-3)
Michaelides M, et al. Ophthalmology. August 2005;112:1442–1447. PMID 15953638. Human phenotype spectrum. (georgiou2020retinalimagingin pages 13-15)
Kitiratschky VBD, et al. Human Mutation. August 2009;30:E782–E796. DOI: 10.1002/humu.21055. Human variants plus biochemical functional testing. (kitiratschky2009mutationsinthe pages 1-3)
Jiang L, et al. PLoS ONE. March 5, 2013;8:e57676. DOI: 10.1371/journal.pone.0057676. L151F model and AAV-RNAi. (jiang2013rnaimediatedgenesuppression pages 13-13, jiang2013rnaimediatedgenesuppression pages 1-2)
Chen X, et al. Genetics in Medicine. August 2017;19:945–954. DOI: 10.1038/gim.2016.217; PMID 28125083. Human R120L family and zebrafish modeling. (chen2017guca1amutationcauses pages 7-8, georgiou2020retinalimagingin pages 13-15)
Marino V, et al. Human Molecular Genetics. December 2018;27. DOI: 10.1093/hmg/ddy311. Human E111V disease and biochemical mechanism. (marino2018anovelp.(glu111val) pages 2-3, marino2018anovelp.(glu111val) pages 8-9, marino2018anovelp.(glu111val) pages 3-3)
Dell’Orco D, Dal Cortivo G. Scientific Reports. December 2019;9:20105. DOI: 10.1038/s41598-019-56606-5. Wild-type GCAP compensation and species differences. (dell’orco2019normalgcapspartly pages 1-2)
Allon G, et al. Investigative Ophthalmology & Visual Science. February 19, 2025;66(2):50. DOI: 10.1167/iovs.66.2.50. Largest GUCA1A clinical cohort and natural-history analysis. (allon2025clinicalgeneticimaging pages 1-2, allon2025clinicalgeneticimaging pages 4-5)

References

(OpenTargets Search: GUCA1A-related retinopathy-GUCA1A): Open Targets Query (GUCA1A-related retinopathy-GUCA1A, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(allon2025clinicalgeneticimaging pages 1-2): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.
(allon2025clinicalgeneticimaging pages 4-5): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.
(marino2018anovelp.(glu111val) pages 3-3): Valerio Marino, Giuditta Dal Cortivo, Elisa Oppici, Paolo Enrico Maltese, Fabiana D’Esposito, Elena Manara, Lucia Ziccardi, Benedetto Falsini, Adriano Magli, Matteo Bertelli, and Daniele Dell’Orco. A novel p.(glu111val) missense mutation in guca1a associated with cone-rod dystrophy leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors. Sep 2018. URL: https://doi.org/10.1093/hmg/ddy311, doi:10.1093/hmg/ddy311. This article has 41 citations and is from a domain leading peer-reviewed journal.
(kitiratschky2009mutationsinthe pages 1-3): Veronique B.D. Kitiratschky, Petra Behnen, Ulrich Kellner, John R Heckenlively, Eberhart Zrenner, Herbert JÃ¤gle, Susanne Kohl, Bernd Wissinger, and Karl-Wilhelm Koch. Mutations in the guca1a gene involved in hereditary cone dystrophies impair calcium‐mediated regulation of guanylate cyclase. Human Mutation, 30:E782-E796, Aug 2009. URL: https://doi.org/10.1002/humu.21055, doi:10.1002/humu.21055. This article has 89 citations and is from a domain leading peer-reviewed journal.
(dell’orco2019normalgcapspartly pages 1-2): Daniele Dell’Orco and Giuditta Dal Cortivo. Normal gcaps partly compensate for altered cgmp signaling in retinal dystrophies associated with mutations in guca1a. Scientific Reports, Dec 2019. URL: https://doi.org/10.1038/s41598-019-56606-5, doi:10.1038/s41598-019-56606-5. This article has 24 citations and is from a peer-reviewed journal.
(jiang2013rnaimediatedgenesuppression pages 13-13): Li Jiang, Tansy Z. Li, Shannon E. Boye, William W. Hauswirth, Jeanne M. Frederick, and Wolfgang Baehr. Rnai-mediated gene suppression in a gcap1(l151f) cone-rod dystrophy mouse model. PLoS ONE, 8(3):e57676, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0057676, doi:10.1371/journal.pone.0057676. This article has 19 citations and is from a peer-reviewed journal.
(marino2018anovelp.(glu111val) pages 1-1): Valerio Marino, Giuditta Dal Cortivo, Elisa Oppici, Paolo Enrico Maltese, Fabiana D’Esposito, Elena Manara, Lucia Ziccardi, Benedetto Falsini, Adriano Magli, Matteo Bertelli, and Daniele Dell’Orco. A novel p.(glu111val) missense mutation in guca1a associated with cone-rod dystrophy leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors. Sep 2018. URL: https://doi.org/10.1093/hmg/ddy311, doi:10.1093/hmg/ddy311. This article has 41 citations and is from a domain leading peer-reviewed journal.
(marino2018anovelp.(glu111val) pages 8-9): Valerio Marino, Giuditta Dal Cortivo, Elisa Oppici, Paolo Enrico Maltese, Fabiana D’Esposito, Elena Manara, Lucia Ziccardi, Benedetto Falsini, Adriano Magli, Matteo Bertelli, and Daniele Dell’Orco. A novel p.(glu111val) missense mutation in guca1a associated with cone-rod dystrophy leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors. Sep 2018. URL: https://doi.org/10.1093/hmg/ddy311, doi:10.1093/hmg/ddy311. This article has 41 citations and is from a domain leading peer-reviewed journal.
(allon2025clinicalgeneticimaging pages 5-10): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.
(marino2018anovelp.(glu111val) pages 2-3): Valerio Marino, Giuditta Dal Cortivo, Elisa Oppici, Paolo Enrico Maltese, Fabiana D’Esposito, Elena Manara, Lucia Ziccardi, Benedetto Falsini, Adriano Magli, Matteo Bertelli, and Daniele Dell’Orco. A novel p.(glu111val) missense mutation in guca1a associated with cone-rod dystrophy leads to impaired calcium sensing and perturbed second messenger homeostasis in photoreceptors. Sep 2018. URL: https://doi.org/10.1093/hmg/ddy311, doi:10.1093/hmg/ddy311. This article has 41 citations and is from a domain leading peer-reviewed journal.
(payne1998amutationin pages 3-3): A. Payne, S. Downes, D. Bessant, R. Taylor, G. Holder, M. Warren, A. C. Bird, and S. Bhattacharya. A mutation in guanylate cyclase activator 1a (guca1a) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1. Human Molecular Genetics, 7(2):273-277, Feb 1998. URL: https://doi.org/10.1093/hmg/7.2.273, doi:10.1093/hmg/7.2.273. This article has 273 citations and is from a domain leading peer-reviewed journal.
(allon2025clinicalgeneticimaging pages 10-13): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.
(allon2025clinicalgeneticimaging pages 13-13): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.
(chen2017guca1amutationcauses pages 7-8): Xue Chen, X. Sheng, Wenjuan Zhuang, Xiantao Sun, Guohua Liu, Xun Shi, Guofu Huang, Yan-fang Mei, Yingjie Li, Xinyuan Pan, Ya-ni Liu, Zi-li Li, Qingshun Zhao, B. Yan, and Chen Zhao. Guca1a mutation causes maculopathy in a five-generation family with a wide spectrum of severity. Genetics in Medicine, 19:945-954, Aug 2017. URL: https://doi.org/10.1038/gim.2016.217, doi:10.1038/gim.2016.217. This article has 26 citations and is from a highest quality peer-reviewed journal.
(allon2025clinicalgeneticimaging pages 2-4): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.
(allon2025clinicalgeneticimaging pages 10-10): Gilad Allon, Siying Lin, Anthony G. Robson, Gavin Arno, Magella M. Neveu, Pirro G. Hysi, Michel Michaelides, Andrew R. Webster, and Omar A. Mahroo. Clinical, genetic, imaging and electrophysiological findings in a cohort of patients with guca1a-associated retinopathy. Feb 2025. URL: https://doi.org/10.1167/iovs.66.2.50, doi:10.1167/iovs.66.2.50. This article has 3 citations and is from a domain leading peer-reviewed journal.
(jiang2013rnaimediatedgenesuppression pages 1-2): Li Jiang, Tansy Z. Li, Shannon E. Boye, William W. Hauswirth, Jeanne M. Frederick, and Wolfgang Baehr. Rnai-mediated gene suppression in a gcap1(l151f) cone-rod dystrophy mouse model. PLoS ONE, 8(3):e57676, Mar 2013. URL: https://doi.org/10.1371/journal.pone.0057676, doi:10.1371/journal.pone.0057676. This article has 19 citations and is from a peer-reviewed journal.
(jiang2012rnainterferencegene pages 158-159): Li Jiang. Rna interference gene therapy for dominant photoreceptor degeneration disease in mouse models expressing mutant guanylate cyclase-activating protein 1. Text, Jan 2012. URL: https://doi.org/10.26053/0h-j46h-jcg0, doi:10.26053/0h-j46h-jcg0. This article has 0 citations and is from a peer-reviewed journal.
(avesani2026retinalnetworkdysfunction pages 12-14): Anna Avesani, Giuditta Dal Cortivo, Sabrina Asteriti, Giorgia Targa, Laura Veschetti, Valerio Marino, Amedeo Biasi, Carmen Longo, Barbara Cisterna, Karolina Saran, Giovanni Malerba, Andrzej T. Foik, Marco Cambiaghi, Lorenzo Cangiano, and Daniele Dell’Orco. Retinal network dysfunction precedes structural degeneration in severe guca1a cone-rod dystrophy. bioRxiv, Jul 2026. URL: https://doi.org/10.64898/2026.06.23.734025, doi:10.64898/2026.06.23.734025. This article has 1 citations.
(georgiou2020retinalimagingin pages 13-15): Michalis Georgiou, Kaoru Fujinami, and Michel Michaelides. Retinal imaging in inherited retinal diseases. Sep 2020. URL: https://doi.org/10.21037/aes-20-81, doi:10.21037/aes-20-81. This article has 53 citations.
(avesani2026retinalnetworkdysfunction pages 14-17): Anna Avesani, Giuditta Dal Cortivo, Sabrina Asteriti, Giorgia Targa, Laura Veschetti, Valerio Marino, Amedeo Biasi, Carmen Longo, Barbara Cisterna, Karolina Saran, Giovanni Malerba, Andrzej T. Foik, Marco Cambiaghi, Lorenzo Cangiano, and Daniele Dell’Orco. Retinal network dysfunction precedes structural degeneration in severe guca1a cone-rod dystrophy. bioRxiv, Jul 2026. URL: https://doi.org/10.64898/2026.06.23.734025, doi:10.64898/2026.06.23.734025. This article has 1 citations.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	10
Resolved	10
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	10
On topic	3
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	1
Resolved	1
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	0
Terms whose name was checked	1
Terms named correctly	0
Terms named as a different term	1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0700376 (4 mentions) - the report calls it "if available", "GUCA1A-related retinopathy"; MONDO calls it GUCA1A-related retinopathy

Terms named inconsistently

The report gives these identifiers more than one name of its own:

MONDO:0700376 - called "if available", "GUCA1A-related retinopathy"

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Progression

Prevalence

Animal Models

Source YAML

References & Deep Research

References

Deep Research

GUCA1A-Related Retinopathy: Disease Characteristics Research Report

Executive summary

1. Disease information

Definition and scope

Identifiers

2. Etiology, risk and protective factors

Causal factor

Genetic risk factors

Modifiers and protective factors

Gene–environment interaction

3. Phenotypes

4. Genetic and molecular information

Gene and variant classes

Modifiers, epigenetics and structural variation

5. Environmental information

6. Mechanism and pathophysiology

Ordered causal chain

Normal pathway and protein dysfunction

Cells, processes and ontology suggestions

Molecular profiling and advanced technologies

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical workflow

Differential diagnosis

Screening

11. Outcome and prognosis

12. Treatment

Current clinical care

Preclinical advanced therapeutics

13. Prevention

14. Other species and natural disease

15. Model organisms

Mouse models (Mus musculus)

Zebrafish (Danio rerio)

Recent developments and evidence gaps

Key primary references

Artifacts

Reference Validation

Term Validation

Terms the report names something else

Terms named inconsistently